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GLUTAREDOXIN-1 REGULATES THE KEAP1-NRF2 PATHWAY 
MAYA HWEWON KIM 
ABSTRACT 
Purpose: The Nrf2/Keap1/ARE pathway is a major regulator of cytoprotective responses 
to oxidants. Gluatredoxin-1 (Glrx-1), a small thiol transferase removes glutathione (GSH) 
adducts from proteins and participates in redox signaling. Glrx-/- mice exhibit increased 
protein GSH adducts (PSSG) and non-alcoholic fatty liver disease (NAFLD). 
Unexpectedly, our Glrx-/- mice showed increased hepatic glutathione (GSH) levels. The 
Nrf2/Keap1/ARE pathway, as an important regulator of glutathione synthesis, could be 
regulated by Glrx-1 activity. 
Methods: To determine the role of Nrf2 in vivo, we treated Glrx-/- mice with high fat 
high sucrose (HFHS) diet to induce metabolic and oxidative stress. Livers were harvested 
at 10 months of age after 8 months on HFHS diet. Gene expression of Nrf2 and its down-
signaling targets were determined using RT-qPCR and protein expression was accessed 
via WB. To determine the role of Nrf2 in Glrx-deficiency in vitro, Glrx siRNA was 
transfected in HEK293A and HepG2 cells and exposed to high palmitate high glucose 
(HPHG) to mimic metabolic stress and hydrogen peroxide to mimic oxidative stress.  
Results: Glrx-/- deficiency increased Nrf2 activity and gene expression, and decreased 
Keap1 activity and gene expression. Glrx silencing in liver promoted Nrf2 activity and 
translocation to the nucleus, and downstream targets of Nrf2 were upregulated. 
Conclusion: Our findings indicate that the Nrf2/Keap1/ARE pathway is regulated by 
Glrx in vitro and in vivo.  
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INTRODUCTION 
NAFLD Definition 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in 
the world1, affecting over one billion individuals worldwide2, with its prevalence 
estimated to be around 20%-40% in adults worldwide3 and reported to be as high as 60% 
in certain urban populations of Western countries4. In the US, NAFLD has evolved to be 
the most serious public health concern, with its prevalence to exceed 30% and to be as 
high as 88% in the obese population5. Currently in the US, NAFLD is the second most 
common cause for liver transplantation3, and is predicted to become the leading cause of 
liver transplantation by the year 20206. 
NAFLD can be divided into two major categories: nonalcoholic fatty liver 
(NAFL) or simple hepatic steatosis, which is defined as the non-progressive form, and 
nonalcoholic steatohepatitis (NASH), which is the progressive form of NAFLD that can 
manifest into liver cirrhosis7,8. The characteristic features of NASH are pronounced 
vesicular steatosis, lobular ballooning and inflammation of the liver with or without liver 
fibrosis9. The pathogenesis of NAFLD, particularly progression to NASH and liver 
fibrosis/cirrhosis is a direct result of the complex interplay between host genetic and 
environmental factors10. Currently, there exists no effective pharmacological treatment 
for NAFLD because of its multifactorial etiology11. Additionally, the molecular signaling 
that contributes to the underlying pathophysiology of NAFLD mirrors that of metabolic 
syndrome (MetS)12. Prior studies have already cemented knowledge linking NAFLD to 
MetS, which encompasses all the risk factors that greatly increase an individual’s 
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probability of developing a wide range of diseases spanning atherosclerosis, 
cardiovascular disease (CVD), Type 2 diabetes mellitus (T2DM), hepatocellular 
carcinoma (HCC) and chronic kidney disease (CKD)13. Because of NAFLD’s close ties 
to MetS, NAFLD remains society’s most daunting health concern and continues to be at 
the center of intense investigation14. 
According to reports from the Worldwide Health Organization (WHO), the 
worldwide prevalence of obesity (defined as body mass index (BMI)>30 kg/m2)15 has 
nearly doubled since 1980, with reports of up to half of the general population being 
classified as overweight in the US16. A systematic review of NAFLD’s epidemiology 
with the nation’s rising obesity epidemic over the past 30 years has verified that NAFLD 
is highest in populations with pre-existing conditions of MetS such as obesity and insulin 
resistance (IR)17. Both obesity and IR are major risk factors for NAFLD with reports of 
up to 90% prevalence of developing NAFLD in obese patients and 70% prevalence of 
developing NAFLD in patients with T2DM18–22. NAFLD pathogenesis is still unclear but 
it has been recognized as the hepatic manifestation of MetS linked to IR from earlier 
studies. They showed that NAFLD patients were more likely to suffer IR compared to 
people without NAFLD23,24, but other reports collected from patients without T2DM 
showed that obese patients with alternative conditions of MetS were more than 2.5 times 
more likely to develop NAFLD than people without MetS associated comorbidities25. 
Collectively, these studies indicate that NAFLD is associated with abnormal metabolism 
caused by metabolic changes rather than simply existing as a manifestation of 
accumulation of excess fat in the liver23. As the nation’s obesity epidemic rises, the 
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prevalence and impact of NAFLD continues to rise as well and currently NAFLD is 
regarded to be the hepatic component of MetS26. It has become common knowledge that 
NAFLD parallels the obesity epidemic and for this NAFLD remains to be one of 
society’s most serious health concerns. 
NAFLD Pathogenesis 
The exact pathogenesis of NAFLD and its progression to NASH is still unknown. 
However what is clear is that NAFLD is the hepatic manifestation of MetS as they share 
many distinct molecular pathways27. The clinical significance of NAFLD has instigated a 
push into scientific investigation into the basic mechanisms involved in NAFLD 
development and progression. Currently, there exists two theories that explain NAFLD 
progression to NASH and they are the “two hit” also called the “double hit” hypothesis 
and the “multiple hits” hypothesis. The first theory, which is the “two hit” hypothesis, 
proposed that the first “hit” involves fat deposition in liver secondary to sedentary 
lifestyle, high consumption of high fat diet (HFD) or lipogenic diet, and the second “hit” 
involves IR and hepatic inflammation brought upon by lipotoxicity, endoplasmic 
reticulum (ER) stress induced mitochondrial dysfunction and oxidative stress, from 
which manifests hepatic steatosis, inflammation and eventual fibrosis28. The “two hit” 
hypothesis is supported by studies using obese mouse models that reportedly developed 
increased hepatic lipid deposition without developing NASH phenotype, as a second 
insult was necessary to initiate hepatic inflammation29. For example, lipogenic diet alone 
was shown to induce NAFLD in ob/ob (obesogenic) mouse line but not cause liver 
inflammation and cirrhosis30. Progression to NASH phenotype was only seen with db/db 
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(diabetic) mouse model with IR fed methionine and choline deficient (MCD) diet31. 
MCD diet alone was shown to initiate NASH in WT mice32–34 and these results seem to 
suggest lipogenic diet or MCD diet, which mimics the effect of over-nutrition seen 
typically in obese mice, is enough to induce NAFLD/NASH progression in mice. This 
theory however proved to be insufficient in explaining NAFLD pathogenesis since it did 
not explain several metabolic changes that occur in NAFLD such as IR, which is now 
considered to be the cardinal sign for NAFLD development35. Additionally, the “two hit” 
hypothesis proposed that fat accumulation has to precede IR and hepatic inflammation, 
which is not always the case for NAFLD pathogenesis36. Recent studies have shown that 
IR actually predisposes hepatic steatosis by establishing lipotoxicity and inducing 
mitochondrial dysfunction in hepatocytes37. NAFLD’s strong link to IR have directed 
many scientists to regard the “multiple hits” hypothesis as the more prospective model to 
explain NAFLD/NASH pathogenesis28. The “multiple hits” hypothesis states multiple 
insults or “hits” whether they are encoded in the hosts genome or arise from 
environmental factors simultaneously occur to give rise to NAFLD phenotype and liver 
fibrosis28. In short, the “multiple hit” hypothesis considers multiple insults acting in 
synergy with the genetic component of a genetically predisposed NAFLD patient to 
explain the pathogenesis of NAFLD. These insults that may simultaneously occur during 
the development of NAFLD, includes obesity, increased hepatic de novo lipogenesis 
(DNL) and lipotoxicity, lipid peroxidation38, IR, hepatocellular inflammation, and 
lipoapoptosis39.  
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Obesity  
Obesity from overconsumption of polyunsaturated fatty acids (PUFAs) and 
resultant IR is the primary risk factor involved in the initial stages of NAFLD40–43. 
Aforementioned, NAFLD is accompanied by obesity and IR44 and progressive 
accumulation of intracellular lipids is thought to sensitize the liver to secondary insults, 
which leads to activation of inflammatory pathways45. Dietary lipids such as omega-6 (n-
6) fatty acids are a family of pro-inflammatory PUFAs that have proven to possess pro-
inflammatory properties46. N-6 fatty acids such as linolenic acid (LA), gamma-linolenic 
acid (GLA) and arachidonic acid (AA) have been shown to induce obesity and promote 
inflammation46 while omega-3 (n-3) fatty acids such as alpha-linolenic acid (ALA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to have 
opposing effects such as anti-inflammatory and lipolytic properties in patients with 
NAFLD47. Currently in the US, high consumption of (n-6) fatty acids and low 
consumption of (n-3) fatty acids, is believed to be the major contributing cause for 
obesity induced NAFLD and IR48,49. Numerous nutritional studies show that obese 
patients with NAFLD/NASH have higher (n-6)/(n-3) fatty acid ratios compared to 
healthy individuals without NAFLD49,50. These new findings suggest that the rise in (n-
6)/(n-3) fatty acid ratios correlate with increased severity of hepatic steatosis. A 2012 
meta-analysis of nine studies showed that fish oil or (n-3) fatty acid supplementation over 
a period of approximately six months proved to have beneficial effects on lowering liver 
enzymes and reducing hepatic steatosis in NAFLD patients5. Since the discovery of the 
beneficial effects of taking fish oil supplements, multiple randomized controlled trials 
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(RCT) have supported the use of omega-3 fatty acids or fish oil supplements for the 
treatment of NAFLD51–53. Decreasing consumption of omega-6 fatty acids like LA, has 
also been proven to lessen the severity of NAFLD54 and increasing consumption of 
omega-3 fatty acids has been shown to normalize liver enzyme levels and improve 
hepatic steatosis55. Additionally, LA, which is the most abundant (n-6) fatty acid 
produced in the body, has the ability to form oxidized linolenic acid metabolites 
(OXLAMs), either enzymatically via 12/15 lipoxygenase or spontaneously in response to 
oxidative stress56. In NAFLD/NASH patients with oxidative stress, increased levels of 
OXLAMS showed to correlate with increased severity of liver fibrosis over time. Animal 
studies showed that 12/15 lipoxygenase knock out (KO) mice had increased hepatic 
inflammation50 and mice fed western diet rich in LA had increased production of 
inflammatory cytokines such as interleukin-1 beta (IL-1B) and tumor necrosis factor 
alpha (Tnfα)57. These experimental studies can be reproduced in human trials and many 
RCTs have assessed the damaging effects of increased dietary LA intake on NAFLD 
progression58,59. A 2012 clinical trial demonstrated that a 12-week reduction in LA 
consumption in NAFLD patients led to decreased levels of circulating OXLAMS in 
blood56. These findings suggest that reduction of LA can benefit patients with high 
inflammatory processes by decreasing endogenous OXLAM synthesis. Moderation of (n-
6) fatty acids, and substituting with (n-3) fatty acids may prevent NAFLD progression. 
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Hepatic de novo lipogenesis (DNL) and lipotoxicity 
When fatty acid input exceeds the capacity for lipolysis or β-oxidation, DNL 
causes hepatic steatosis, which is an underlying feature of NAFLD. NAFLD is associated 
with a multitude of diseases but hypertriglyceridemia or increased triglyceride (TG) 
synthesis is a primary feature of NAFLD29. Free fatty acid (FFA) from diet or adipose 
tissue undergo the process of hepatic DNL via activation of certain transcription factors 
which includes sterol regulatory element-binding protein factor 1c (SREBP-1c), 
carbohydrate response element-binding protein (ChREBP) and peroxisome proliferator-
activated receptor (PPAR)60. SREBP-1c is stimulated by insulin signaling via insulin 
receptor substrate 2 (IRS-2) to directly activate hepatic DNL61,62 and SREBP-2 regulates 
cholesterol homeostasis63. With IR, IRS-2 is up-regulated, thereby causes SREBP-1c to 
become overexpressed and overactive, which ultimately leads to increased hepatic 
DNL64. ChREBP has been shown to be stimulated by glucose to increase hepatic DNL65. 
Intriguingly, ChREBP may have cytoprotective functions in NAFLD as one report 
showed that the loss of ChREBP in mice fed high fructose diet led to increased hepatic 
steatosis and inflammation. This study seemed to suggest that prior studies linking 
ChREBP overexpression in NAFLD was due to over activation of pro-apoptotic 
pathways induced by oxidative stress29. Lastly, PPAR-γ has been shown to induce 
NAFLD phenotype in mice fed obesogenic diet via activation of lipogenic factors 
implicated in fatty acid synthesis and increased hepatic DNL66.  
Excess FFA exist in the liver as triglycerides (TG)67,68. Adipocytes readily store 
excess TG but when FFA influx becomes too great and exceeds storage capacity, TG 
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stores are converted to TG intermediates such as diacylglycerol (DAG), ceramides and 
FFA, all of which are toxic metabolites that lead to cellular damage and increase IR39. 
This phenomena of TG metabolite mediated cellular dysfunction has been described as 
lipotoxicity68–70. Studies have shown that TG retention in livers via inhibition of 
microsomal triglyceride transfer protein (MTP) did not induce NAFLD71 but impaired 
TG formation via inhibition of diacylglycerol acyltransferase 2 (DGAT2) expression 
worsened NAFLD phenotype72. These studies suggest that TG accumulation alone is not 
enough to induce NAFLD but increased concentration of TG intermediates can induce 
lipotoxicity to cause injury to the liver69,70. Additionally, one study found that TG storage 
in liver via diacylglycerol acyltransferase 1 (DGAT1) reduced the level of IR in mice 
model with NAFLD72. 
Lipid peroxidation 
With over-accumulation of PUFAs, lipids become susceptible to oxidative 
degradation by ROS species in particular hydroxyl radical and hydrogen peroxide. This 
ROS mediated chain of reactions has been termed lipid peroxidation73. The process of 
lipid peroxidation is a self-perpetuating process and only ceases to continue with the 
generation of a non-radical, which is the product of collision between two ROS species, 
which would only occur during conditions of oxidative stress, in which high 
concentrations of radical species would lead favor the likelihood of collision74.  Many 
enzymes such as catalases (CAT) and superoxide dismutases (SOD) exist to defend 
against auto-peroxidation of lipids and many antioxidants including vitamin E has been 
shown to aid in the formation of non-radical species in the termination stage of lipid 
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peroxidation75. Buildup of toxic metabolites has been shown to cause liver dysfunction 
and lead to the NAFLD development74,76. Recently vitamin E therapy has been shown to 
be a therapeutic strategy for the treatment of NAFLD and NASH by decreasing PPAR 
gene expression and increasing expression of eukaryotic initiation factor 2 (EIF-2), which 
serves a cytoprotective role under conditions of ER stress. Earlier studies have confirmed 
the therapeutic potential of vitamin E by showing decreased ER stress, decreased ROS 
formation and improved hepatic steatosis in patients with NAFLD with vitamin E 
supplements77–79.  
Insulin Resistance (IR) 
IR is considered to be a principle key pathogenic factor for NAFLD 
development80. The underlying pathogenesis of NAFLD is complex but all current 
theories propose increased fat consumption can lead to IR development, which has been 
shown to worsen NAFLD phenotype in obese patients. In fact, obesity induced IR is 
believed to be the primary initiator driving NAFLD/NASH pathogenesis81. T2DM is the 
disease characterized by IR and multiple reports have confirmed its association to 
NAFLD in its regards to glucose intolerance, hyperlipidemia and IR82. Its important to 
note that IR seen in NAFLD pathology does not stem from T2DM and multiple studies 
have shown NAFLD patients without T2DM report decreased insulin sensitivity and 
increased IR mediated hepatic steatosis83–85. NAFLD and NASH patients with IR from 
obesogenic diet have increased hepatic DNL and impaired lipolysis, which the combined 
effect is hepatic steatosis86. Even though NAFLD is strongly associated with IR, we 
cannot consider NAFLD to be a consequence of IR87,88. In fact, Glrx-/- mice fed HFD did 
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not show IR even though they showed prominent hepatic steatosis indicative of NAFLD 
physiology89. These reports of liver damage seen in non-diabetic mice support the fact 
that NAFLD may occur independent of IR by showing the disconnection between 
NAFLD pathogenesis in the absence of confounding effects seen by deregulated insulin 
signaling. Additionally, IR has been shown to promote hepatocellular inflammation by 
regulating the activity of certain adipokines mainly leptin and adiponectin and increasing 
the secretion of pro-inflammatory cytokines such as Tnfα and IL-680.  
Hepatocellular Inflammation 
 In obesity induced NAFLD patients there is increased expression of inflammatory 
genes and macrophage activation that correlate with progression from simple steatosis to 
NASH to liver cirrhosis/fibrosis. Under obesogenic conditions, adipokines such as 
adiponectin and leptin maintain a low-grade pro-inflammatory state and this low-grade 
chronic inflammatory state or “metabolic inflammation” is what underlies the 
development of IR and NAFLD90,91. With NAFLD development and increased flux of 
FFA, the level of inflammatory mediators such as leptin’s level of pro-inflammatory 
activity is maximized and this phenomenon is called hepatocellular inflammation, which 
is what is thought to drive disease progression into NAFLD and IR92–95. 
Lipoapoptosis 
Lipotoxicity is known to promote hepatic apoptosis which has also been called 
lipoapoptosis in the context of NAFLD96,97. Lipoapoptosis is defined as unregulated 
hepatic apoptosis and is included one of the defining characteristic of NAFLD and 
NAFLD progression9897. In patient studies, lipoapoptosis has been positively correlated 
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with NAFLD progression and severity in liver injury99. In hepatocytes, lipoapoptosis is 
mediated by members of the Bcl2 family of proteins, which includes its binding partner 
Bcl2 binding component 3 (Bbc3) also known as p53 up-regulated modulator of 
apoptosis (Puma). Two mechanisms of lipoapoptosis include the intrinsic apoptotic and 
extrinsic apoptotic pathway. The intrinsic pathway is elicited in response to 
mitochondrial dysfunction and ER stress whereas the extrinsic pathway is activated via 
increased fatty acid synthesis, death ligands, and Tnfα regulated apoptosis inducing 
ligand (TRAIL). Activation of either apoptotic pathway results in activation of the Bcl2 
family of proteins including Bbc3, which in turn activates the pro-apoptotic cascade via 
induction of pro-apoptotic and proteolytic enzymes. Activation of these pro-apoptotic 
enzymes in the mitochondria has shown to increase mitochondrial dysfunction and result 
in hepatic injury attributed to NAFLD pathogenesis. 
NAFLD Causes and Diagnosis 
In the clinic, NAFLD is believed to be caused by an excessive accumulation of fat 
in the liver in the absence of alcohol consumption11. The majority of NAFLD patients, 
around 20-30% of patients, are asymptomatic and present only with hepatic steatosis also 
called simple steatosis but around 2-3% of these patients develop concurrent pathological 
liver inflammation with/without liver fibrosis, which is the characteristic hallmark of 
NASH3. The disease rarely further progresses to liver cirrhosis and approximately 10-
25% of NASH patients may progress to liver failure23. In absence of cirrhosis, 
approximately 25%-45% of NASH patients actually develop HCC100. Clinically, NAFLD 
is diagnosed by a hepatic triglyceride level that exceeds 5% of the total liver weight in the 
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absence of post-secondary causes of steatosis101 such as excess alcohol consumption102, 
hepatomegaly103, hepatitis C virus (HCV)102,104, hepatitis B virus (HBV)102, familial 
hypobetalipoproteinemia (FHBL)105, and endocrine disorders106. Additionally, NAFLD 
patients consistently show elevated levels of liver enzymes, which are released as a result 
of liver injury, are used as definitive biomarkers for clinically diagnosing NAFLD107,108. 
The list of liver enzymes include alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP) 
as well as C-reactive protein (CRP). In healthy patients, the AST/ALT ratio is normally 
less than one, but AST/ALT ratio increases with NAFLD progression109.  
Pathological features of NAFLD include simple steatosis, hepatic ballooning, 
immune cell infiltration, and necrosis101. Specific notable histological features of NAFLD 
are Mallory’s hyaline within the cytoplasm of a ballooning hepatocyte110 and 
perisinusoidal fibrosis mostly seen in the centrilobular zone III in adults25. Increased 
hepatic reticuloendothelial iron deposition is closely associated with advanced degree of 
NAFLD111 but the impact of iron regulators like hepciden and ferroportin in NAFLD and 
NASH remains largely elusive112. Studies have shown that many NAFLD patients report 
having increased serum hepciden levels113. Additional research looking at differentially 
expressed genes related to iron overload in NAFLD and NASH patients have shown 
increased hepciden levels in NAFLD may serve to mitigate inflammatory processes in the 
NAFLD to NASH transition114. Regulating iron overload may serve as an efficacious 
therapeutic measure in NAFLD treatment. 
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Even though liver biopsy remains the “gold standard” for NAFLD diagnosis115, a 
non-invasive screening of fatty liver by abdominal ultrasonography is also used to 
diagnose NAFLD116. Histological examination of liver from biopsy has its limitations as 
it is prone to sampling error116, as a single puncture only accounts for about 1/50,000th 
the size of the whole liver117. In most instances there are no complications, but there 
exists some risks, which include internal bleeding, bile leakage from gallbladder 
puncture, and pneumothorax from chest wall puncture exist118. Given these limitations 
and invasive nature, many patients decline the procedure, and instead opt for 
ultrasonagraphy, which offers accurate detection of hepatic steatosis117. However, 
ultrasonography itself is prone to significant sampling error and to overcome its 
limitations transient elastography (TE) has been developed119. The TE technology, known 
commercially as Fibroscan®, has shown promising results in liver steatosis and fibrosis 
assessment and consequently has been integrated into the regulatory guidelines for 
diagnosis of liver damage by HCV or HBV120. To further increase TE’s efficacy, the 
controlled attenuation parameter (CAP) was created to serve as a regulatory guideline to 
accurately evaluate the stages of steatosis121. In recent years, Fibroscan®-CAP has shown 
great potential in confirming the diagnosis of NAFLD, and by working by the properties 
of ultrasonic signals, it serves as the ultimate tool in measuring the level of liver stiffness 
and steatosis122. An advantage of TE technology has been its ability to detect liver 
volume that is at least 100 times greater than the size of a single percutaneous liver 
biopsy. Another positive aspect of TE technology is that it is a fast non-invasive method 
that is more cost-effective and more procurable from NAFLD patients123.  
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The proper diagnosis of NAFLD requires hepatic steatosis with the exclusion of 
alcohol abuse or other identifiable causes because the proper distinction between host 
genetic factors that are responsible for NAFLD should be separated from any 
compounding external environmental factors that may complicate accurate prognosis of 
NAFLD124. Currently three approaches to NAFLD management exist and they include 
lifestyle changes (i.e. diet and exercise), medication, and surgical interventions125. 
Diet & Exercise 
The only current treatment for NAFLD is making lifestyle changes in diet and 
exercise that would lead to a reduction in BMI, but these lifestyle changes are difficult to 
implement and sustain over lifetime126. Although behavioral interventions aimed at 
managing pediatric obesity showed reversible weight loss and slowed progression of 
pediatric NAFLD to NASH among other metabolic conditions such as T2DM127, it is 
unclear whether this is also true in the adult population as adult patients with NAFLD 
exhibit a spectrum of obesity related co-morbidities that include hypertension128, 
dyslipidemia129, T2DM130, CKD131 including obstructive sleep apnea132,133 that can 
complicate NAFLD etiology. A recent observational study that was an eight year follow 
up study of obese patients with NAFLD revealed that NAFLD could be reversed through 
weight loss by lifestyle modifications, but NAFLD regression was only seen in a small 
percentage of these patients134. A study showed that NAFLD patients, who benefitted 
from clinical treatment and physical therapy, had improved outcomes in NAFLD that 
were associated with increased hospital visits135. The therapeutic role of physical activity 
and subsequent weight loss on NAFLD pathophysiology has been established in multiple 
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animal studies as well as clinical trials. A prospective study that was a seven year follow-
up study showed that a modest weight loss of 3-5 kg could lead to remission of NAFLD 
regardless of BMI136. The results of this study were further supported by two additional 
reports that showed that a modest weight loss of even 2 kg could attenuate NAFLD137,138. 
Another cross-control study that examined the effect of lifestyle factors such as diet, 
exercise and sleep on NAFLD showed that maintaining proper dietary habits, physical 
activity and sleep would contribute to greatest mitigation of NAFLD phenotype139. 
Additional studies that investigated the effect of physical activity supported the inverse 
association between the level of physical activity and NAFLD severity, by showing 
attenuation of visceral obesity and improvement in IR140. These studies seem to indicate 
gradual weight deduction by reduced caloric intake and/or increased physical activity is 
the primary strategy for NAFLD management141. Additional experimental studies have 
demonstrated that mice fed excess cholesterol had a higher likelihood of developing 
NAFLD even in the absence of obesity142,143 and mice fed high fat diet containing at least 
1% cholesterol could develop NAFLD despite changes in BMI144. These studies seem to 
indicate that dietary patterns specifically consumption of hyper-caloric diet rich in 
trans/saturated fats and cholesterol, are more important contributors to NAFLD 
development and progression to NASH. Current management of NAFLD remains to be 
gradual weight loss through moderation in diet and habitual physical exercise, but 
development of a healthy lifestyle is difficult to achieve and hard to implement over a 
long time period. Nonetheless, multiple sources from literature propose that a routine 
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management in diet and exercise is the ultimate strategy for prolonged remediation of 
liver injury145.  
Pharmacotherapy of NAFLD 
Current pharmacologic treatment of NAFLD patients involves the use of a 
combination of a list of drugs owing to the account of NAFLD being a multisystem 
disease146. In other words, no single therapy exists to effectively treat NAFLD48,147.  The 
list of current medications used to treat NAFLD include ursodeoxycholic acid (UDCA), 
insulin sensitizers (metformin and pioglitazone), anti-fibrotic agents such as 
pentoxifylline and natural antioxidants (coffee, tea and vitamin E)148 and nuclear receptor 
agonists involved in lipid metabolism PPAR, farnesoid X receptor (FXR), and liver X 
receptor (LXR))149. From the list of drugs used to treat NAFLD, pioglitazone and vitamin 
E have proven to be the most effective in the treatment of NAFLD in non-diabetic 
patients150. Over the years, numerous studies have tested the safety and efficacy of these 
medications to develop the best strategy in combatting NAFLD but clinical data suggest 
medications alone are not adequate therapies for NAFLD129. 
Ursodeoxycholic acid (UDCA) 
UDCA is a non-hepatotoxic epimer of chenodeoxycholic acid, which is one of the 
two primary bile acids produced and stored in the gallbladder. UDCA, as a secondary bile 
acid, has been primarily used in the treatment of gallstones and primary biliary cirrhosis 
(PBC). UDCA was shown to improve cholestasis and minimize hepatic toxicity in 
patients with PBC. However, in NAFLD patients, UDCA was shown to decrease liver 
enzyme levels and exert anti-inflammatory effects151. Numerous RCTs support the 
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beneficial effects of UDCA administration on NAFLD patients by showing decreased 
aminotransferase levels and reduced histological progression of NAFLD upon UDCA 
treatment. Results from an RCT showed how two years of UDCA therapy benefited 
patients with NASH by decreasing levels of liver aminotransferases and lowering levels 
of hepatic steatosis152. A systematic review, showed UDCA administration with vitamin 
E supplementation significantly improved hepatic steatosis and inflammation in NASH 
patients, whereas UDCA administration alone did not show significant changes in ALT 
levels or improvement in liver pathology153. Interestingly an RCT comparing the 
beneficial effects of vitamin E to UDCA treatment, showed UCDA was a safe and 
effective alternative drug to vitamin E treatment in alleviating NAFLD in non-diabetic 
patients154. But additional studies showed that vitamin E based therapy in conjunction 
with UDCA administration in patients with NAFLD led to significant decreases in liver 
enzyme levels155. One RCT looking at UDCA’s effects on obese patients with chronic 
NAFLD, showed that UDCA treatment prevented increased cholesterol and bile acid 
synthesis to normalize hepatic lipid levels156. Combinatorial treatment of patients with 
NAFLD and NASH with UDCA and vitamin E might offer the best therapeutic results by 
decreasing liver enzyme secretions and improving histological progression of 
NAFLD157,158. Other studies looking at a shortened derivative of UDCA called 24 nor-
ursodeoxycholic acid (NorUDCA) showed that it could reduce levels of hepatic steatosis 
and inflammation and thus be used as a new therapeutic agent for treatment of 
NAFLD159. An interesting open-labeled study that looked at whether minimizing 
oxidative stress by vitamin E and vitamin C therapy could be effective in normalizing 
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liver aminotransferase levels, showed vitamin E plus vitamin C treatment was just as 
effective as combinatorial treatment with vitamin E and UDCA in patients with fatty 
liver160. Other studies that looked at UDCA combined with angiotensin-II type I receptor 
blocker showed that the combinatorial treatment reduced hepatic fibrosis in rat model 
with NASH161. Interestingly, a study comparing the effects of resveratrol (RSV), N-
acetylcysteine (NAC) and UDCA in rat model with NAFLD showed that while a 
combination of all three drugs effectively worked to ameliorate NAFLD, RSV was the 
best at reducing liver enzymes, exerting anti-inflammatory effects and reducing lipid 
levels in liver162. Despite these minor discrepancies within the research community on 
UCDA’s potential as the new therapeutic drug for the amelioration of NAFLD, what is 
clear is the fact that UCDA is beneficial for the treatment of NAFLD and NASH by 
working to reduce liver aminotransferase levels, hepatic steatosis and inflammation and 
ultimately lipid accumulation in the liver163. Numerous reports now support the protective 
effects of UDCA on fatty liver diseases such as NAFLD and NASH but the many adverse 
side effects and drug interactions of UDCA has proven to be problematic for individuals 
sensitive to drug-induced effects164. In summary, UDCA has proven to be a useful non-
toxic therapeutic agent with long-term tolerability165.  
Insulin sensitizers 
Metformin has shown to reduce IR and lower liver aminotransferase levels in 
obese patients with NAFLD but show little improvement in liver histology166. Results of 
an open-label study showed metformin treatment of one year improved liver enzyme 
levels and IR within the first three months of treatment but found levels quickly returned 
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to existing levels after the three months167. One RCT revealed that metformin with 
vitamin E supplementation showed the effect of lowering of liver aminotransferase 
levels, suppressing IR and diminishing levels of hepatic steatosis and inflammation in 
liver histology168. In another RCT, NAFLD patients on diet and exercise prescribed 
metformin showed a reduction in ALT levels and complete normalization of ALT after 
six months treatment169. Despite the positive signs in NAFLD mitigation in response to 
metformin therapy, recent reports of open-labeled pilot studies refute the benefits of 
metformin on liver steatosis and inflammation because of lack of histological 
improvement170. Additional studies have questioned the lasting impact on the beneficial 
properties of metformin on NAFLD by criticizing metformin’s inability to reduce liver 
enzyme levels for a prolonged period of time171. Currently, metformin as of yet has not 
been included in the list of potential treatments for NAFLD and further evidence, 
specifically dose-dependent studies, are needed to evaluate the optimal dosage 
parameters for safety and efficacy for administration of these drugs for NAFLD 
treatment172. Research has been ongoing to develop new insulin sensitizers that work in 
concert to improve IR and improve metabolic function to offer greater histological 
resolution of NAFLD.  
Pioglitazone has also been shown to reduce liver aminotransferase levels, improve 
IR, decease hepatic steatosis and inflammation173. With respect to oxidative stress, 
pioglitazone attenuates oxidative damage in hepatocytes of mice fed HFD via increased 
antioxidant defense and enhanced DNA repair mechanism174. In one RCT, pioglitazone 
exerted the same kind of benefits as vitamin E by normalizing hepatic aminotransferase 
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levels however it was reported that combination of pioglitazone treatment with vitamin E 
showed the most improvement in NAFLD histology175. In clinical practice, NAFLD 
patients undergoing pioglitazone treatment reported conditions of weight-gain, edema 
and heart failure as serious side effects in patients with pre-existing CVD176. In one RCT, 
pentoxifylline and pioglitazone treatments were compared and pioglitazone was found to 
have better outcome with lower of aminotransferase levels, lower hepatic inflammation, 
and better overall liver histology compared to results from pentoxifylline therapy177. 
Based on the prior research, it has been determined that pioglitazone should best be 
prescribed to non-diabetic patients without conditions of pre-existing congestive heart 
failure178. In a landmark RCT comparing placebo vs. pioglitazone vs. vitamin E study for 
treatment of non-diabetic NAFLD patients called the PIVENS trial, it was found that 
taking pioglitazone (30 kg/mg/day) for up to one year showed drastic reduction in liver 
enzyme levels and restored liver histopathology179. More research is warranted to further 
elucidate the benefits of pioglitazone and to establish the long-term safety profile in 
administering this drug in the treatment of NAFLD178.  
Pentoxifylline 
Pentoxifylline is an anti-fibrotic agent other than FXR agonists that is under 
intense investigation for NAFLD treatment180. Pentoxifylline participates in the inhibition 
of cytokine Tnfα, which is involved in instigating the inflammation cascade in disease 
progression from NAFLD to NASH181. In an open-label pilot study, pentoxifylline (400 
kg/mg/day) was shown to improve liver aminotransferase levels in NAFLD patients 
when they were administered the drug for a one year period182. Similarly in another open-
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label pilot study, pentoxifylline was shown to exhibit similar benefits by improving liver 
aminotransferase levels, decreasing liver steatosis and inflammation and liver fibrosis183. 
In contrast, recent studies aimed at evaluating the efficacy of pentoxifylline compared to 
atorvastatin treatment showed that pentoxifylline even at high concentrations of 800 
kg/mg/day did not significantly decrease levels of ALT and AST or improve levels of 
hepatic steatosis and inflammation as effectively as the alternative drug atorvastatin, 
which was shown to significantly attenuate steatosis and improve liver function184. In 
recent years there have been numerous other reports citing the marginal efficacy of drugs 
like pioglitazone, pentoxifylline and vitamin E in the treatment of NAFLD as they do not 
directly improve liver function185–187. Many potential NAFLD therapies have been 
suggested but these therapies have shown to be suboptimal as no single pharmacological 
agent can successfully alleviate the multitude of treatment targets that is associated with 
NAFLD48. These treatment targets include weight loss, lowering of blood glucose, drop 
in lipotoxicity and lipogenesis, anti-inflammation, insulin sensitizing, anti-apoptosis and 
anti-fibrosis188. Given the high prevalence of NAFLD, new combination therapy that 
takes into account each treatment target is warranted180.  
Natural Antioxidants  
NAFLD is considered a multifactorial disease in relation to pathogenic 
mechanisms. Oxidative stress has a major implication in NAFLD pathogenesis. The 
deleterious effects of oxidants and suppression of antioxidant pathways in NAFLD has 
been suggested in many studies and clinical use of natural antioxidants has shown 
therapeutic potential by decreasing lipid oxidation, steatosis and fibrosis189. The use of 
	   22	  
antioxidants for NAFLD treatment has remained the subject of many experimental 
studies and clinical trials since the discovery of its anti-oxidative properties190.  
Vitamin E 
Vitamin E (also known as α-tocopherol) is the most studied antioxidant treatment 
option and is the preferred treatment in non-diabetic patients with histology proven 
NAFLD and NASH. To study the effect of antioxidants in children with pediatric 
NAFLD without IR, vitamin E was administered for at least four-ten months and results 
showed a marked improvement in hepatic aminotransferase levels191. In another RCT 
comparing vitamin E to metformin treatment in children with pediatric NAFLD in the 
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) trial, results showed 
that neither vitamin E nor metformin offered any beneficial effect in reducing hepatic 
aminotransferase levels or decreasing liver steatosis and inflammation192. In addition a 
post-hoc study showed vitamin E consumption was associated with reduced NAFLD 
pathophysiology compared to placebo, but these changes did not include improvement in 
IR, decreased hepatic steatosis, decreased fibrosis or complete recovery of liver 
function193. However in the PIVENS trial, which is the largest clinical trial up to date, 
vitamin E was found to reduce liver aminotransferase levels, decrease liver steatosis and 
inflammation and improve liver histology in adult NAFLD patients without T2DM176. An 
earlier RCT, which compared effects of healthy eating/exercise, UDCA, and vitamin E 
found that NAFLD patients in the lifestyle intervention plus UDCA and vitamin E 
treatment group showed the most decline in liver enzyme levels and improvement in liver 
steatosis and inflammation155.  
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Coffee  
Coffee has been regarded as the most commonly consumed beverage in the world 
and fortunately is a rich source of antioxidants which has been shown to slow the 
progression of fibrosis in NAFLD194. The protective antioxidant effects of coffee in 
NAFLD have long been established with reports of regular coffee consumption leading to 
improved liver enzyme levels, decreased inflammation and decreased fibrosis195. 
Multiple reports now support the inverse correlation between coffee consumption and 
NAFLD, for instance one proteomics study found coffee consumption increased 
chaperone and antioxidant protein expression in ER that resulted in reduced inflammation 
and fibrosis in livers of NAFLD rats fed HFD196. Another study, which further explored 
coffee’s antioxidant effect, reported that rats that were subjected to diet-induced MetS 
and fed coffee extract, showed improved glucose tolerance and liver function but no 
overall changes in abdominal obesity and dyslipidemia197. However, results from a meta-
analysis of four cross-sectional studies combined with three case control studies, which 
reviewed the impact on coffee consumption on lowering fibrosis in patients with 
NALFD, revealed that total caffeine consumption did not significantly lower the 
prevalence of NAFLD or slow the progression of liver fibrosis and cirrhosis198. 
Additionally, results from a systematic review and meta-analysis of pooled observational 
studies, suggested moderate coffee consumption did not lower fibrosis scores in NAFLD 
patients with MetS199. A large community based study reporting on the beneficial effects 
of coffee, reported no evidence for association between coffee consumption and severity 
of NAFLD200. Retrospective studies also looking at the beneficial effects of coffee on a 
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patient population with early onset NAFLD, reported no association between coffee 
consumption and disease progression of NAFLD but suggested coffee consumption may 
exert beneficial effects on fibrosis progression in NAFLD201. Surprisingly, some studies 
showed that only large coffee consumption elicited protective antioxidant properties 
against NAFLD199,201,202. However, numerous reports have shown the dangers of high 
coffee intake such as development of hypertension203,204. 
Nonetheless, a study found that among NAFLD patients coffee drinkers who 
drank up to two cups of coffee per day had lower risk of developing NAFLD compared to 
non-coffee drinkers195,205,206. Coffee consumption has been associated with lower IR and 
one RCT showed that lowering of IR via moderate coffee consumption led to a lower risk 
of severe fibrosis in patients with NAFLD207. Earlier clinical trials have linked coffee 
consumption to improved IR202, decreased development of T2DM208–210 and improved 
cardiovascular function155,156 but showed no affect in altering fat accumulation in liver, 
which is the main cause of NAFLD197,211. Recent studies have supported coffee’s 
beneficial effects on NAFLD by showing decreased plasma AST/ALT, reduced liver 
inflammation and fibrosis and by showing overall improvement in liver function212. 
Despite all evidence, its important to keep in mind that these studies also assert no 
confirmative association between coffee consumption and the new onset of 
NAFLD195,201,209,211. From clinical data, regular coffee consumption seems to have 
therapeutic benefits but the question to whether regular coffee consumption can 
completely prevent the progression of NAFLD is up for debate.  
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Tea 
Natural polyphenol antioxidants from fruits/vegetables are the emerging class of 
drugs being proposed for NAFLD treatment194. Flavonoids such as quercetin, rutin and 
troxerutin, which are abundant in red onions, apples, berries, and red wine, have been 
associated with NAFLD attenuation via increased β-oxidation of FFAs and lipid 
transport213–215. Numerous studies have demonstrated quercetin’s potent antioxidant 
properties in liver during experimentally induced liver injury216–218. One study showed 
quercetin treatment improved insulin sensitivity, increased adiponectin levels, increased 
Tnfα levels and reduced hepatic steatosis in NAFLD mice fed Western diet219. Later 
research from the same NAFLD mice fed Western diet revealed that quercetin suppressed 
accumulation of immune cells and promoted gene expression of oxidative stress induced 
transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and 
antioxidant enzymes220. Quercetin has also been shown to be a potent activator of nuclear 
factor erythroid 2-related factor 2 (Nrf2) by inhibiting Nrf2 ubiquitination, promoting 
Nrf2 stabilization and ultimately prolonging Nrf2 half-life, all of which worked to 
increase transcriptional activity of Nrf2221.  Studies in HepG2 cell line have shown 
quercetin treatment increased gene expression of phase II detoxification enzymes such as 
glutamylcysteine-synthetase (GCS), glutathione peroxidase (GSH-Prx) and glutathione 
reductase (Gsr) as well as glutathione (GSH) levels222. Quercetin stimulation of Nrf2 has 
been well documented in cancer cells such as mesothelioma cells223 and breast cancer 
cells224. One study showed that quercetin treatment in rats with NAFLD could prevent 
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liver damage and promote cardiac remodeling by effectively inducing NF-κB and Nrf2 
along with its subsequent downstream targets225. Interestingly, new research supports 
quercetin may alleviate NAFLD by modulating gut microbiome and inhibiting intestinal 
inflammation219.  
Flavanols called catechins also possess antioxidant properties and specific 
examples include epicatechin (EC), epigallocatechin (EGC), and epigallocatechin gallate 
(EGCG)226. These catechins, which are abundant in green tea leaves, react with 
polyphenol oxidase to lead to the production of second level flavonoids such as 
theaflavins and thearubucin, which are polyphenol antioxidants found abundant in black 
tea227. Theaflavins and thearubucin act as effective scavengers for reactive oxygen 
species (ROS), specifically superoxide and hydrogen peroxide species that cause cellular 
damage.  Theaflavins and thearubucin have been associated with suppressing oxidative 
stress via inhibiting NF-κB, protein kinase B (Akt) and transforming growth factor beta-1 
(TGF-β1) signaling228–230. Interestingly, black tea has been shown to be more effective 
than green tea by inducing β-oxidation via AMPK activation in liver hepatocellular cells 
(HepG2 cells) and mouse livers with NAFLD fed HFD231. Nonetheless, theaflavin-1 has 
been shown to reduce hepatic steatosis and inflammation in mice fed Western diet232,233. 
In addition to its ability in inhibiting inflammation, tea polyphenol antioxidants have 
been shown to inhibit certain kinases involved in redox pathways such as inducible nitric 
oxide synthase (iNOS), lipoxygenases and cyclooxygenases that play major roles in 
NAFLD pathogenesis234. Tea polyphenols have also been shown to inhibit xanthine 
oxidase, which is the enzyme that reduces molecular oxygen to superoxide and hydrogen 
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peroxide, which are ROS species that contributes to oxidative stress in liver235. A recent 
study demonstrated that tea antioxidant properties offered protection against lipogenic 
diet-induced NAFLD via ROS-dependent mechanisms in primary cultured hepatocytes 
from rats fed HFHS diet236. In mice, consumption of green tea extract, which has the 
greatest antioxidant to polyphenol oxidase ratio, were shown to have reduced liver 
steatosis and inflammation when given at least 2% green tea extract for eight consecutive 
weeks237. One RCT, revealed NAFLD patients who received green tea extract showed 
improvement in serum ALT, AST, GGT and ALP levels, which serves as an accurate 
indicator of recovery of liver function238. Epidemiologic studies have produced 
contradictory findings regarding the beneficial effect of tea antioxidants on NAFLD but 
an overwhelming majority of data seems to suggest an inverse relation between tea 
consumption and NAFLD progression239–241. Currently the medical urgency, which has 
sparked an intense interest in, the treatment of NAFLD, has provided new insight into the 
possible role of antioxidants in NAFLD treatment and has suggested novel therapeutic 
measures and diagnostic techniques to prevent liver damage. 
Nuclear Receptor Agonists 
 The development of PPAR agonists, which act as insulin sensitizers to regulate 
multiple metabolic processes like β-oxidation of free fatty acids and lipid transport, has 
shown promising results in reducing hyperlipidemia but has not been shown to 
significantly benefit obese patients with NAFLD242,243.   
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Surgical Intervention 
Given the increasing surge of NAFLD patients, there has been a greater demand 
for liver donors as the need for liver transplants greatly outnumber the amount of 
available livers244. However, for most obese patients with NAFLD without hepatic 
fibrosis and liver cirrhosis liver transplantation is unnecessary and other effective 
measures for weight reduction are recommended. The list of treatment options for obesity 
related NAFLD include lifestyle intervention, anti-obesity medications, and bariatric 
surgery. Among the list of available options, bariatric surgery has proven to be the most 
reliable method for achieving sustained weight loss44. Over the years, with advancement 
in surgical technology and refinement in surgical technique, bariatric surgery has become 
a safe and routine operation. Among patients with severe obesity, bariatric surgery has 
been a popular option and has even been nicknamed “metabolic surgery” in reference to 
the resultant weight loss245. Bariatric surgery is associated with improved liver enzyme 
levels and improved liver histopathology, thus it remains one of the more attractive 
candidates for obesity induced NAFLD treatment246.  
Oxidative Stress and Redox Signaling  
Oxidative stress, which is cellular redox imbalance, is the main contributing 
factor in liver injury and NAFLD progression247–249. Oxidative stress is defined as an 
imbalance in oxidative metabolism due to increased ROS in response to ineffective 
antioxidant defense174. However, the pathogenesis of NAFLD and its progression to 
NASH is still unknown250. Current research indicates altered redox signaling from 
mitochondrial dysfunction is the contributing factor associated with NAFLD 
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pathogenesis251. ER stress is a well-known causative agent for NAFLD development, 
which results in mitochondrial dysfunction in hepatocytes. Mitochondrial dysfunction is 
the main source of ROS in fatty liver and serves as a stimulus for lipotoxicity and hepatic 
inflammation252. Mitochondria are main sites of ROS production from leaky electron 
transport chain (ETC) and hydrogen peroxide (H2O2) and hydroxyl radicals (-OH) are the 
main forms of ROS produced during mitochondrial respiration and β-oxidation253. As by-
products of aerobic respiration, ROS levels have been associated DNA instability/damage 
that contribute to the aging process254. Additionally, ROS levels have also been linked to 
development of hepatic inflammatory disorders such as NAFLD and NASH255,256.   
In redox signaling, cysteine residues of proteins existing as sulfhydryls become 
susceptible to oxidation by oxidants to form mixed protein disulfide bonds with GSH. 
This process is commonly referred to as sulfenic acid reactions or first degree oxidation 
reactions as this modification in protein structure alters and inactivates protein 
function257. Disulfide bond formation is reversible meaning they can be reduced back to 
sulfhydryls by disulfide reductases such as thioredoxin (Trx), peroxiredoxin (Prx) and 
glutaredoxin (Glrx also known as Glrx-1), which function to recycle proteins back to 
their original functional state258. However, in conditions of oxidative stress, increasing 
levels of hydrogen peroxide drive the equilibrium in favor of oxidative processes, which 
results in the formation of sulfinic (-SO2H) or sulfonic (-SO3H) species (Fig. 2.). Cellular 
defense mechanisms to prevent oxidative stress induced cell necrosis/death are able to 
remove oxidants via the actions of SOD, CAT and GSH-Prx258. In cells, hydrogen 
peroxide is always generated from superoxide, which can be formed by reduction of 
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molecular oxygen by NADPH oxidases259,260 or by superoxide dismutase 1 (SOD1) and 
superoxide dismutase 2 (SOD2) by spontaneous dismutation260. Increased superoxide 
levels is associated with oxidative stress and they have been shown to damage proteins 
containing Fe-S clusters258. Hydroxyl radicals are another type of ROS that are generated 
by hydrogen peroxide in the presence of ferrous or copper ions by the Fenton Reaction. 
Hydroxyl radicals have been shown to be particularly damaging to cellular lipid 
membranes and DNA174. 
Glutaredoxin (Glrx) and Glutaredoxin System 
Glrx is the primary redox enzyme responsible for regulating oxidative stress261. 
Glrx, as the primary sulfhydryl reductase, plays a central role in antioxidant defense by 
reducing mixed protein disulfides (PSSG) formed between two cysteines in the process 
known as reversible glutathionylation or de-glutathionylation of protein sulfhydryls262. 
Mammalian Glrx contains the active motif Cys-Pro-Tyr-Cys263 and two reactive cysteine 
residues at catalytic sites Cys22 and Cys25 that catalyze glutathione (GSH)-dependent 
thiol disulfide redox reactions264,265. GSH is a low molecular weight thiol that consists of 
glutamate, cysteine and glycine. GSH is a highly abundant antioxidant that defends 
against oxidative stress and has been confirmed as a key antioxidant in redox signaling. 
Endogenous GSH is produced by ATP-dependent reactions catalyzed by glutamate-
cysteine ligase (GCL) and GSH synthase266. 
In the Glrx/GSH system, Glrx is itself oxidized by substrate (PSSG) and is 
reduced non-enzymatically by GSH267. In the presence of high levels of hydrogen 
peroxide, GSH-Prx uses the reducing potential of GSH to reduce disulfide bonds of 
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proteins. In this reaction hydrogen peroxide gets reduced to water and GSH oxidized to 
GSSG (Fig. 1.). By this reaction, GSH-Prx uses GSH as a redox cofactor to effectively 
glutathionylate proteins but the overall reaction is a two step reaction that uses a total of 
two GSH molecules268. Initially the selenothiol (R-Se-H) group of hydrogen peroxide 
gets oxidized to produce selenenic acid (R-Se-OH), but gets reduced back to R-Se-H by 
GSH to produce R-Se-GS intermediate. In the next set of reactions, another GSH reduces 
R-Se-GS intermediate back to R-Se-H to ultimately release GSSG269.  Once oxidized 
GSSG is generated it is reduced back to GSH by the actions of Gsr, which uses NADPH 
as an electron donor to start this recycling process all over again (Fig. 1.). In this way, 
Glrx acts as a thiol transferase by using co-factor GSH, which is dependent on the 
activity of Gsr and NADPH. Nicotinamide nucleotide transhydrogenase (NNT) is an 
enzyme located inside the mitochondrial matrix that contributes to NADPH production. 
NNT actually works to increase NADPH/NADP+ ratio by catalyzing NADP+ reduction 
and NADH oxidation to allow proton entry back into mitochondrial matrix270. By this 
mechanism, NNT functions in the regeneration of NADPH, which is important as 
NADPH plays a major role in hydrogen peroxide detoxification271. Multiple studies have 
shown NNT silencing results in decreased NADPH production, increased GSSG 
mediated oxidative stress, and increased hydrogen peroxide mediated cellular 
dysfunction272. It is worth mentioning that all intracellular antioxidants rely upon 
NADPH as a reducing equivalent and NADPH is also needed as a cofactor for Trx and 
GSH reductases273. NADPH oxidases also use the reducing power of NADPH to perform 
their function to generate free radicals like ROS. Studies have also found NADPH 
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accumulation and subsequent increased activity of NADPH oxidase was responsible for 
increased ROS levels and ROS mediated apoptosis, which are attributed to cancer 
development274. Interestingly, inhibition of fatty acid synthase (Fasn) induced hepatic 
DNL, was shown to increase activity of NADPH oxidase and prevent accumulation of 
NADPH275. Additionally, liver tumorigenesis studies reported that increased NADPH 
oxidase activity led to overall improvement in hepatic DNL and decreased GSH adducts 
were also observed276.  Intracellular NADPH is generated by the reduction of NADP+ by 
glucose-6-phosphate dehydrogenase (G6pd), which is considered an essential regulatory 
antioxidant enzyme that provides a steady pool of NADPH and maintains GSH/GSSG 
balance277,278. It is important to note that changes in ratio of oxidized glutathione to 
reduced glutathione (GSSG/GSH) is used as a marker for oxidative stress174.  
In a process known as cysteine S-glutathionylation, which is a reversible 
modification of cysteines by glutathione S- transferase (Gstp1), increased levels of PSSG 
causes disulfide/thiol exchange between PSH and PSSG to produce GSH species279. In a 
way, cysteine S-glutathionylation can be thought of as the exact reversal of de-
glutathionylation seen in glutaredoxin reactions (Fig. 2.). Gstp1, as the name implies, 
functions by reversibly transferring GSH adducts to proteins280 and also is a 
detoxification enzyme in phase II conjugation reactions281. The main difference between 
the two sets of reactions is that de-glutathionylation reaction by Glrx involves GSH 
usage, while cysteine S-glutathionylation reactions by Gstp1 leads to GSH production282. 
In cells, both processes involving forward reactions by Gstp1 and reverse reactions by 
Glrx work in conjunction to maintain redox homoestasis283(Fig. 2.).  ROS and ROS 
	   33	  
metabolites have proven to be hard measures to detect in conditions of NAFLD255. 
Recently, measurement of cysteines has been suggested to be a marker of oxidative stress 
and NAFLD/NASH progression, as cysteine residues of thiol groups have been shown to 
undergo cysteine modifications such as protein S-sulfhydration and S-nitrosylation 
reactions that cause hepatocellular damage284. Hydrogen sulfide (H2S) induces protein S-
sulfhydration to form sulfinic (SO2H) and sulfonic (SO3H) species285 and reactive 
nitrogen species (RNS) cause protein S-nitrosylation (R-SNO), all of which cause lipid 
peroxidation and DNA damage286. Finally thiol radicals have also been shown to be 
modified by zinc277 and iron-sulfur (Fe-S) clusters278 of certain proteins, as these metals 
are known to be excellent electron donors. Altogether, uncontrolled oxidative 
modification of thiol radicals has been shown to greatly alter redox homeostasis, cause 
oxidative stress induced inflammation/apoptosis, and instigate NAFLD.  In summary, the 
Glrx/GSH pathway keeps redox homeostasis in check and ensures low oxidative 
conditions but when this cytoprotective mechanism become ineffective, other 
cytoprotective processes including activation of the Nrf2/Keap1/ARE signaling cascade 
may be stimulated. 
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Figure 1. Glrx/GSH system. Protein GSH-adducts (Protein-SSG) is formed by reactive 
oxygen species (ROS) and oxidized glutathione (GSSG) by glutatredoxin (Glrx). GSSG 
is reduced back to reduced glutathione (GSH) by glutathione reductase (Gsr) by using 
nicotinamide ademine dinucleotide phosphate (NADPH) as an electron donor. Also 
shown are monothiol and dithiol deglutathionylation reactions which are the same 
reactions and the product of the reaction is a mixed protein disulfide (Glrx-S-SG). 
Oxidized Glrx (Glrx-SS) formation and oxidized glutathione (GSSG) are also products of 
both reactions. 
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Figure 2. Cysteine S-glutathionylation. In cells, an increased GSSG/GSH ratio is 
indicative of oxidative stress, which drives the equilibrium in favor of oxidative 
processes, which results in the formation of sulfinic (-SO2H) or sulfonic (-SO3H) species. 
Unlike sulfenic acid (R-SOH), sulfinic and sulfonic species are irreversible and 
consequently result in permanent cellular damage/apoptosis. Under oxidative conditions, 
increased ROS drives de-glutathionylation of free thiols (Protein-SH) to form mixed 
protein disulfides (Protein-SSG). Redox homeostasis is held in check by Glrx, Trx, and 
Prx, which reduce disulfide bonds of Protein-SSG back to Protein-SH. Adapted from289. 
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Nuclear factor erythroid 2-related factor 2 (Nrf2) 
The Nrf2/Keap1/ARE signaling pathway is a major regulator of cytoprotective 
responses with many downstream targets including detoxification enzymes and 
antioxidants that collectively function to reduce ROS mediated lipotoxicity290. The key 
players of this pathway are Nrf2 also known as nuclear factor erythroid-derived 2- like 2 
(NFE2L2), kelch-like ECH associating protein 1 (Keap1), antioxidant response element 
(ARE) and small Maf proteins. Nrf2 is a basic leucine zipper (bZIP) transcription factor 
that regulates expression of antioxidant genes during conditions of oxidative stress and 
inflammation291. Keap1 serves as a suppressor of Nrf2 by binding to Nrf2 and promoting 
its degradation by the ubiquitin proteasome pathway. Keap1 is a cysteine rich protein that 
is vulnerable to cysteine modifications290 and studies have found Keap1 to be 
glutathionylation by Gstp1 in conditions of oxidative stress292. In recent studies, 
napthoquinone, which is a pro-oxidant species, was shown to glutathionylate Keap1 at 
Cys368 and Cys513, whereby the effects were shown to suppress inflammation293. The 
exact mechanism in which cysteine modifications of Keap1 leading to Nrf2 release and 
subsequent translocation to the nucleus is still unknown but the prevailing model is the 
“hinge and latch” theory. The “hinge and latch” model suggests Keap1 modifications in 
sulfhydryl residues of the IVR region disrupt its binding interaction with Nrf2 causing 
modification of lysine residues of Nrf2 that can no longer make it susceptible for 
polyubiquitination. It has been confirmed that upon oxidative/electrophilic stress the 
three cysteines at C151, C273, and C288 are modified, which ultimately disrupts Keap1 
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binding to Nrf2290. Another theory suggests that upon oxidative/electrophilic stress, 
cysteine modifications of Keap1 actually disrupt the association between Cul3 and 
Keap1294. Normally, in conditions of low oxidative stress, Nrf2 is constantly 
ubiquitinated by Cul3-Keap1 ubiquitin E3 ligase complex. However, upon increased 
exposure to oxidative stress, reactive cysteine residues of Keap1 become modified 
leading to instability in interaction with Cul3. This leads to a decline in E3 ligase activity 
and subsequent dissociation of Nrf2 from Keap1 in the cytoplasm to be translocated to 
the nucleus294. Upon Nrf2 entering the nucleus, it binds to ARE via heterodimerization 
with small Maf proteins, which are thought to stabilize their interaction295,296. Nrf2 
transcription factor itself contains two transcription activation domains called Nrf2 ECH 
homology 4 (Neh4) and Nrf2 ECH homology 5 (Neh5) domains that serve as the two 
main regulators of gene transcription297. Multiple studies have shown that 
phosphorylation of Nrf2 at Ser40 by protein kinase C (PKC) can lead to the release and 
activation of Nrf2 from Keap1 but is not required as other mechanisms may be at play for 
Nrf2 activation298. Nrf2 regulates the transcription of a wide array of lipogenic enzymes 
involved in detoxification/cytoprotection and cholesterol synthesis as well as antioxidants 
including: (1) phase 2 detoxifying enzymes such as Gstp1299, glutamate-cysteine ligase 
catalytic (GCLC) subunit and NAD(P)H quinone oxidoreductase 1 (Nqo1)299 (2) 
lipogenic enzymes such as Fasn300 and stearoyl-CoA desaturase (Scd1)300 and (3) 
enzymes involved in cholesterol synthesis such as 3-Hydroxy-3-Methylglutaryl-CoA 
reductase (Hmgcr)301 (4) antioxidative defense enzymes such as heme oxygenase 1 
(Hmox1)299, SOD1, and SOD2302, (5) enzymes involved in NADPH regeneration such as 
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G6pd 303 and malic enzyme 1 (Me1)303, (6) enzymes involved in ROS mediated 
apoptosis/autophagy such as TP53 induced glycolysis and apoptosis regulator (Tigar)304 
and Bbc3302. 
Fatty acid synthase (Fasn) 
Fasn is a lipogenic enzyme that catalyzes the synthesis of palmitate from acetyl-
CoA and malonyl-CoA, and thus is a key enzyme in de novo fatty acid synthesis302. 
Studies have shown that SREBP-1c and ChREBP are major regulators of Fasn302. 
NAFLD and IR has been associated with increased Fasn expression by insulin induced 
activation of sterol regulatory elements (SRE) and carbohydrate-responsive elements 
(ChORE), which has just been described as FASN promoters to induce Fasn 
expression294.  
Stearoyl-CoA desaturase 1 (Scd1) 
Scd1 is a lipogenic enzyme that catalyzes the synthesis of monosaturated fatty 
acids (MFA) from saturated fatty acids (SAF). MFAs are directly involved in increased 
TG synthesis and TG accumulation in liver, which results in the development of NAFLD. 
Studies have shown increased MFA synthesis by Scd1 results in NAFLD302. In rats and 
mice models, increased levels of Scd1 were associated to diet induced obesity, hepatic IR 
and progression of fatty liver305. Other reports showed Scd1-/- mice fed MCD diet had 
decreased hepatic steatosis, significantly decreased levels of saturated fatty acid 
accumulation in liver306. In human trials, increased Scd1 levels were correlated with 
NAFL severity and worsened hepatic lipogenic index307. All reports show Scd1 as a key 
lipogenic enzyme that results in increased hepatic steatosis. In contrast to prior findings, 
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recent studies have shown decreased Scd1 levels in HFD-induced fatty livers of rats 
without IR compared to rats with IR fed a normal chow diet, these results indicate that 
Scd1 is not a sole determining factor for the development of fatty liver308. 
3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr) 
The liver is the primary site for cholesterol synthesis and Hmgcr is a rate-limiting 
enzyme responsible for cholesterol synthesis309. Hmgcr exists anchored to the ER and 
functions to regulate cholesterol synthesis by a negative feedback mechanism mediated 
by sterols derived from mevalonate240. Normally de novo cholesterol synthesis in liver is 
regulated by internalization of low density lipoprotein (LDL) via LDL receptor and the 
scavenger receptor class B type I (SR-BI) but with increased plasma cholesterol 
concentration Hmgcr is suppressed and cholesterol synthesis ceases310. In obese patients 
with NAFLD, Hmgcr is upregulated in the liver so that cholesterol synthesis is always 
turned on310. 
NAD(P)H quinone dehydrogenase 1 (Nqo1) 
Nqo1 is a 2-electron reductase that reduces quinones to hydroquinones and 
prevents the ROS production by quinones. Nqo1 is primarily involved in the 
detoxification reaction, which relies on NADPH as a electron donor. In this way, Nqo1 
serves as an important detoxifying agent present in all cells. Nqo1 has been seen to play a 
role in ubiquinone and vitamin E quinone metabolism, which have been found to possess 
protective antioxidant properties and have been shown to protect cellular membrane from 
oxidative stress299. Multiple studies have confirmed that Nqo1 gene expression is 
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regulated by the Nrf2/Keap1 pathway and Nqo1 has been confirmed as a target of 
Nrf2/Keap1 signaling311. 
Heme oxygenase 1 (Hmox1) 
Hmox1 is an essential enzyme of heme metabolism that catalyzes the cleavage of 
heme to form biliverdin, which is the substrate for bile acid production. Bilirubin is 
formed from biliverdin by the actions of biliverdin reductase and becomes bound to 
albumin to be transported to the liver where it becomes conjugated with glucuronic acid. 
Conjugated bilirubin joins bile acids also produced in the liver to be freely released from 
the body. Interestingly, studies have confirmed an inverse relationship between bilirubin 
levels in the plasma with NAFLD progression312,313. One recent clinical study, which 
examined the levels of bilirubin in NAFLD patients, found patients with low to moderate 
risk for NAFLD development possessed the highest levels of bilirubin in plasma while 
chronically ill NAFLD patients reported the lowest levels of bilirubin. The results of this 
study shows that elevated bilirubin levels were significantly correlated with decreased 
risk of developing NAFLD314. As a promoter of bilirubin synthesis, Hmox1 has also been 
shown to be directly upregulated in patients with NAFLD315. In animal studies, treatment 
with cilostazol and probucol, both of which are anti-inflammatory and anti-oxidative 
agents, were seen to significantly increase Hmox1 levels, decrease liver enzyme levels 
and reduce expression of lipogenic genes SREBP-1c and Fasn that are responsible for 
hepatic steatosis and NAFLD301. In cell culture experiments, hepatocytes when grown 
under hypoxic conditions to imitate the oxidative stress seen in NAFLD, showed to have 
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increased Hmox1 expression along with increased expression of lipogenic and 
inflammatory genes, all of which are hallmark indicators for NAFLD progression316. 
Glucose-6-phosphate-dehydrogenase deficiency (G6pd) 
Aforementioned, G6pd is involved in the regeneration of NADPH and research 
shows G6pd deficiency causes depletion of NADPH in red blood cells317 and complete 
lack G6pd is embryolethal318. In animal studies, decreased G6pd levels were shown in 
HFD induced fatty livers of rats compared to livers of rats fed standard diet (SD). 
Additional rodent studies, also reported decreased plasma G6pd levels with HFD-induced 
oxidative stress in rats319. Hence, G6pd can be seen as a major player in maintaining 
redox homeostasis and regulating glucose metabolism via NADPH production319. In fact, 
over-expression of G6pd has been associated with obesity, IR severity, increased hepatic 
steatosis and development of fatty liver319. 
Superoxide dismutase 1 (Sod1) and Superoxide dismutase 2 (Sod2) 
Sod1 and Sod2 enzymes catalyze the dismutation of superoxide into molecular 
oxygen and hydrogen peroxide. Aforementioned, superoxide and hydrogen peroxide are 
examples of ROS, which participate in oxidative damage. Given superoxide is a 
metabolite of oxygen metabolism their levels are strictly controlled by SOD and CAT, 
which specifically degrades hydrogen peroxide. Thus, SOD are involved in antioxidant 
defense by reducing ROS levels in the cell to prevent oxidative damage. Interestingly, 
CAT TG mice were shown to exhibit decreased ROS mediated oxidative stress, 
decreased PSSG and improved cardiac function320. NAFLD patients have shown to have 
decreased SOD activity resulting from poor antioxidant defense from ROS that has been 
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attributed to oxidative stress321. ROS induction of hepatic steatosis and inflammation, 
both of which are hallmark features of NAFLD progression, has been well documented 
and new studies show that rising levels of ROS may be inhibiting antioxidants like GSH-
Prx and SOD322. Research on mice models with NAFLD showed that oxidative stress 
induced expression of a wide array of Nrf2 targets including SOD antioxidant genes323. 
Additionally, mouse models of NAFLD showed that IR severity was positively 
associated with increased expression of SOD1 and SOD2314. 
Malic enzyme 1 (Me1)  
Me1, also known as malate dehydrogenase or NADP-malic enzyme (NADP-ME), 
catalyzes the decarboxylation of malate to pyruvate in the presence of co-factor NADP+. 
Me1 acts as an oxidoreductase in the decarboxylation reaction, in which malate is 
oxidized to pyruvate and carbon dioxide and NADP+ is reduced to NADPH. Like G6pd, 
Me1 is an NADPH generating enzyme involved in anabolic processes such as triglyceride 
synthesis and hepatic DNL. Increased gene expression of Me1 has been linked to 
increased hepatic steatosis in mice fed high fructose diet324. In rats with NAFLD, one 
study showed that RSV treatment actually attenuated Me1 levels along with acyl-
coenzyme A (ACO), Fasn, and G6pd levels, in addition to reducing levels of oxidative 
stress and hepatic steatosis324. 
TP53 induced glycolysis and apoptosis regulator (Tigar) 
Tigar is a p53-induced regulator of apoptosis that plays an essential role in 
cytoprotection from ROS mediated apoptosis. Numerous studies have shown Tigar 
expression correlates with cytoprotective mechanisms of the cell during conditions of 
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oxidative stress325. Tigar has been known to suppress ROS levels via p53, and increase 
GSH levels and overall protect cells from oxidative damage298,326. Tigar is an essential 
regulator of the pentose phosphate pathway (PPP) and has been shown to promote 
synthesis of ribose-5-phosphate for DNA synthesis. Tigar is also an essential regulator of 
metabolic pathways and essentially acts as fructose-2,6-bisphosphatase to promote 
cellular growth/proliferation. Tigar has also been shown to have antioxidant function via 
upregulation of PPP to produce NADPH327. In relation to NAFLD, no current studies 
have examined the effects of increased Tigar expression on NAFLD regression but from 
prior studies the, mechanisms involved may be more complex than what we initially 
thought.  
Bcl2 binding component 3 (Bbc3) 
Bbc3 also known as Puma is a p53-induced regulator of apoptosis. Following 
exposure to oxidative stress, Bbc3 interacts with other anti-apoptotic Bcl2 family of 
proteins, which ultimately inhibits Bbc3’s interaction with pro-apoptotic proteins such as 
Bcl2 associatiated X protein (Bax) and Bcl2 homologous antagonist killer (Bak)68. In 
normal conditions, tumor suppressor p53 facilitates Bbc3 interaction with Bax or Bak so 
that the newly formed heterodimer complex can be activated and translocated to the 
mitochondria, where it functions to induce mitochondrial dysfunction and activate 
apoptosis by caspases, which are a family of proteases that are responsible for 
apoptosis68. The master regulators of hepatic apoptosis are Bbc3 and the members of 
Bcl2 family of proteins, but Bbc3 binding to Bcl2 has been found to be both dependent 
and independent of p53 activity328. In connection to NAFLD, increased Bbc3 activity has 
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been associated to NAFLD severity and inhibition of anti-apoptotic Bcl2 was found to be 
the main contributing factor in NAFLD progression328,329. Additional studies on mice 
with high cholesterol diet (HCD)-induced NAFLD showed increased levels of p53 and 
increased Bbc3 expression in livers. The study also reported an increased expression of a 
wide range of apoptotic proteins including all member of Bcl2 family of apoptotic 
proteins, second mitochondrial derived activator of caspases (SMAC), caspases, and 
apoptosis-inducing factor (AIF) in NAFLD mice fed HCD compared to WT mice fed 
SD330. In patients with NAFLD, careful analysis of their liver histology revealed a 
positive correlation between p53 activation and the progression of hepatic steatosis and 
fibrosis seen in NAFLD331. Recent research shows that loss of regulatory control of p53 
results in fatty liver disease and resultant apoptosis, liver steatosis and fibrosis331–334. All 
reports support p53 plays a central role in the development of hepatic fibrosis and 
subsequent Bbc3 activation has been linked to NAFLD pathogenesis. 
Glutathione S-transferase Pi 1 (Gstp1) 
Gstp1 belongs to a family of enzymes involved in antioxidant defense and cell 
survival335,336. Aforementioned, Gstp1 is a detoxifying enzyme, which functions to 
detoxify proteins via cysteine S-glutathionylation of proteins337,338, which is essentially 
the process of protein conjugation with GSH298,339–342. In cysteine S-glutathionylation of 
proteins, Gstp1 essentially acts as a thiol transferase between PSH and PSSG to produce 
GSH species279. Numerous studies have acknowledged Gstp1 as a potent antioxidant that 
works to protect cells from oxidative damage343. Gstp1 has been also described as an 
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endogenous regulator of JNK activity, which is responsible for cellular proliferation, 
survival and apoptosis344–347. 
Hypothesis and Aims 
Over the years, there has been a recent expansion in the development of 
therapeutic strategies to reduce ROS levels and prevent lipotoxicity in the progression of 
NAFLD348. Given the high abundance of intracellular GSH, research studies have looked 
at the role of GSH as a key redox sensitive marker of oxidative stress and have found 
increased formation of protein-GSH adducts in livers of mice with NAFLD89. Since Nrf2 
directly controls GSH synthesis, we hypothesized that altered GSH homeostasis via Glrx 
deficiency would induce Nrf2 levels and increase gene expression of down signaling 
targets of Nrf2. The aims of our study were to show Glrx-/- mice fed HFHS diet (1) 
developed obesity and NAFLD (2) had increased gene expression of detoxifying 
enzymes involved in antioxidant defense and (3) had increased gene expression of Nrf2 
and down signaling targets of Nrf2. To demonstrate further Glrx regulation of Nrf2, 
additional aims of our study were to show (1) increased Nrf2 protein levels with Glrx 
knockdown in HEK293 and HepG2 cells treated with HPHG and hydrogen peroxide and 
(2) increased Nrf2 protein levels with Glrx knockdown in HepG2 cells. In our study, our 
results showed Glrx-/- mice fed chow diet and HFHS diet developed obesity and NAFLD, 
had increased gene expression of phase II detoxifying enzymes and antioxidants, 
increased Nrf2 translocation and activation of Nrf2 target genes compared to livers of 
WT mice on chow and HFHS diet. Our results suggest that Nrf2 may be regulated by 
Glrx deficiency and Glrx may act as a feedback regulator of Nrf2. Aforementioned, Nrf2 
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is a known inducer of increased gene expression of a list of antioxidants, phase II 
detoxifying enzymes, NADPH oxidases, lipogenic enzymes, enzymes involved in 
cholesterol synthesis and regulators of antioxidant defense which includes Glrx349. It 
would be reasonable to hypothesize GSH accumulation from Glrx deficiency could be 
driving a feed forward stimulus for Nrf2 activation to activate Nrf2 down signaling 
targets.   
METHODS 
 
Animals 
 Glrx-/- mice were obtained from Dr. Y.S. Ho lab (Wayne State University, Detroit, 
MI) and backcrossed to C57BL6/NJ (20g-25g) in Dr. Janssen-Heininger’s lab (University 
of Vermont, Burlington, VT) or backcrossed with C57BL6/J mice in our lab, these mice 
in addition to having Glrx KO, also had NNT KO. All animals were maintained in the 
animal housing facility at BUSM and acclimated in 12hr light and 12hr dark cycles and 
were fed standard chow or HFHS diet ad libitum. Mice with “none J” (NJ) backcross 
were fed normal diet (ND) (constituted with 4.5% fat, 0.02% cholesterol) or HFD 
(constituted of 21% representing 42% calories, 34% sucrose, and 0.2% cholesterol, 
TD.88137; Harlan, South Easton, MA) for 3 months.  Mice with J background were fed 
HFHS diet (#D0907170, Research Diets, New Brunswick, NJ) or chow diet 
(#D09071703, Research Diets, New Brunswick, NJ) starting at 2 months of age for a 
total of up to 8 months before being sacrificed. Animals were euthanized by isoflurane 
gas at approximately 3-5% induction before being sacrificed and organs were harvested 
and immediately snap frozen in liquid nitrogen for preservation of tissue integrity. Livers 
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for mRNA analysis were stored at -80oC. Housing and experimental procedures were in 
accordance with the Guide for the Care and Use of Laboratory Animals as determined by 
the U.S. National Institutes of Health. 
RNA Isolation and RT-qPCR 
 RNA isolation was performed using RNeasy Lipid Tissue Mini Kit (QIAGEN, 
Germantown, MD) as per manufacturer’s protocol. RNA concentrations were determined 
via Nanodrop UV Visible Spectrophotometer (ThermoFisher Scientific, Waltham, MA). 
RNA integrity and purification was determined by GelRed (Biotium, Fremont, CA) 
stained agarose gel electrophoresis. Reverse transcription of RNA to cDNA was 
performed using High-Capacity RNA to cDNA kit (ThermoFisher Scientific, Waltham, 
MA). Quantitative PCR was carried out using gene-specific TaqMan primers (Invitrogen 
by ThermoFisher Scientific, Waltham, MA): Rps18 (Mm02601777_g1), Glrx 
(Mm00728386_s1 and Hs00829752_g1), Fasn (Mm00662319_m1), Scd1 
(Mm00772290_m1), Hmgcr (Mm01282499_m1), Tnfα (Mm00477784_m1), IL-6 
(Mm00446190_m1), Nrf2 (Mm00477784_m1), Nqo1 (Mm01253561_m1), G6pdx 
(Mm00656735_g1), Hmox1 (Mm00516005_m1), Sod1 (Mm01344233_g1), Sod2 
(Mm01313000_m1), Me1 (Mm00782380_s1), Gsr (Mm00439154_m1), Gstp1 
(Mm00496606_m1), Bbc3 (Mm00519268_m1), and Tigar (Mm00621530_m1). Gene 
expression levels were measured by taking comparative CT (ΔΔ CT) values with 
StepOne RT-qPCR software (Applied Biosystems, Foster City, CA). 
Cell Culture and siGlrx Transfection 
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HEK293A (ATCC, Manassas, VA) cell-lines were used in this study to determine 
Glrx regulation of Nrf2. Cells were separated into control (5mM glucose, 0.67% BSA), 
high palmitate high glucose (HPHG; 400 µM glucose, 0.4 mM palmitic acid, 0.67% 
BSA), and hydrogen peroxide (HP, 50 µM) treatment groups to study the effect of 
metabolic and oxidative stress on Nrf2 signaling. HEK293A and HEPG2 cells were 
plated in 6 well plates until cells reached 80% confluence or a cell density greater than 
2.0-X 104 cells/well. Both cell lines were maintained from passages 2-7 in high glucose 
DMEM (ThermoFisher Scientific, Waltham, MA) supplemented with 10% FBS, 
100units/ml of penicillin, and 100µg/ml streptomycin. After reaching 80% confluency, 
cells were transfected with siGlrx (ThermoFisher, Waltham, MA) or scrambled with 
control siRNA (GE Dharmacon, Lafayette CO) via Lipofectamine 2000 (Invitrogen by 
ThermoFisher, Waltham, MA) according to the manufacturer’s protocol. After 6hr 
transfection with siRNA-lipofectamine complex, medium was changed to low glucose 
DMEM and cells were incubated for additional 48hr unless cells were subject to HPHG 
or HP conditions. Cells in the HPHG groups were treated with HPHG media 16hr after 
transfection and cells in HP groups were treated with 50µM hydrogen peroxide for 1hr 
duration before cells could be harvested for protein analysis.  
Western Blot (WB) 
 Cells and liver tissue were lysed in RIPA buffer (150mM NaCl, 5mM EDTA (pH 
8), 50mM Tris (pH 8), 1% NP-40, 0.5% SDS, 0.1% sodium deoxycholate) substituted 
with cOmplete Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO) and HALT 
Phosphatase Inhibitor Cocktail (ThermoFisher Scientific, Waltham, MA). After protein 
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concentration was assayed with DC Protein Assay (Bio-Rad, Hercules, CA), and 2X 
Laemmli buffer (Bio-Rad, Hercules, CA) was added and lysates were incubated 95oC for 
5mins. To detect disulfide bonds, 2-mercaptoethanol was added to maintain reducing 
conditions. Prepared samples were loaded onto 15% Tris-glycine polyacrylamide gels 
(freshly prepared) or commercially available Tris-Glycine 4-12% gradient gels (Novex, 
Invitrogen by Thermo Fisher Scientific, Waltham, MA). Precision Plus Protein Dual 
Standards (Bio-Rad, Hercules, CA) marker was used on all gels. After separation by 
electrophoresis, proteins were transferred to a Immobilon-PSQ Membrane (EMD 
Millipore, Bedford, MA). Blots were blocked in 5% skim milk (Fisher Scientific, 
Waltham, MA) prepared in PBS with 1% Tween 20. For WB analysis the following 
primary antibodies (1:1000) were used to detect respective protein expression levels:  
Glrx (IMCO by Cayman Chemical, Ann Arbor, MI), Nrf2 (Cell Signaling, Beverly, MA), 
Keap1 (Cell Signaling, Beverly, MA), and beta-actin (Cell Signaling, Beverly, MA). The 
membranes were incubated with appropriate antibodies overnight at 4oC and were then 
incubated with the appropriate secondary antibodies (1:3000) for 1 hour. Detection was 
performed using the Amersham ECL Prime Western Blotting Detection Reagent (GE 
Healthcare Life Sciences, Pittsburg, PA) and SuperSignal West Dura Chemiluminscent 
Substrate (ThermoFischer Scientific, Waltham, MA) on HyBlot CL Autoradiography 
Film (Denville Scientific Inc., Holliston, MA). 
Statistics 
 All data are expressed as (means ± SEM). Statistical analysis comparing two 
groups was carried out using the nonparametric Mann–Whitney test. Analysis of more 
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than two groups was performed either by one-way ANOVA or two-way ANOVA. 
Sequential measurements were analyzed by repeated measure one-way ANOVA. P < 
0.05 was considered significant. All analysis was performed using GraphPad Prism 5.0. 
WB image analysis was performed using Image J software. 
RESULTS 	  
Glrx-/- mice on HFHS diet develop obesity and NAFLD 
Previous studies from Shao et al. showed Glrx-/- mice fed chow diet became obese 
and developed NAFLD at ten months of age89. We used multiple methods of histological 
staining including Oil Red O and hematoxylin and eosin (H&E) staining to confirm 
hepatic steatosis in livers of our Glrx-/- mice (Fig. 3. and Fig. 4). To show hepatic 
inflammation and hepatic injury in our Glrx-/- mice, we measured with RT-qPCR 
expression of IL-6 and pro-inflammatory cytokine Tnfα in the livers of our Glrx-/- mice 
fed both chow and HFHS diet (Fig. 5B.). To show Glrx-/- livers developed obesity after 
ten months on chow diet, mRNA expression levels of Fasn and Scd1, which are 
regulators of DNL biosynthesis in liver, and Hmgcr, which is the rate limiting enzyme in 
cholesterol synthesis, were measured and showed to be increased in Glrx-/- livers (Fig. 
5A.). Overall, our findings confirmed Glrx KO in liver promoted hepatic fatty acid 
deposition via increased hepatic DNL and cholesterol synthesis that led to development 
of NAFLD but the effects were exacerbated when Glrx-/- mice were fed HFHS diet and 
progressed to NASH. Furthermore, Shao et al. detected no up-regulation of inflammatory 
cytokines in Glrx-/- mice fed chow. Mice in the previous study were on C57BL/6 NJ 
background with an intact NNT and were less susceptible to metabolic stress. In this 
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study, Glrx-/- mice were backcrossed to C57BL/6 J, and as expected reacted more 
sensitively to metabolic changes. C57BL/6 J Glrx-/- mice fed chow diet developed NASH 
as characterized by extensive ballooning of hepatocytes and up-regulation of cytokines. 
Figure 3. 
 
           
    A.                                                                         B. 
           
    C.                                                                         D.  
Figure 3. Glrx-/- mice fed chow diet developed NAFLD. Representative histological 
images of H&E stained livers of (A) WT mouse fed chow diet (B) WT mouse fed HFHS 
diet (C) Glrx-/- mouse fed chow diet and (D) Glrx-/- mouse fed HFHS diet. All of the 
histological examinations used hematoxylin and eosin staining. Scale bar, 20 µm. 
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Figure 4.  
 
      
A.                                                                 B. 
      
     C.                                                                   D. 
Figure 4.  Glrx-/- mice fed HF diet developed NAFLD. Representative histological 
sections of Oil Red O stained livers of (A) WT mice fed chow diet. (B) Glrx-/- mice fed 
chow diet (C) WT mice fed HF diet and (D) Glrx-/- mice fed HF diet. Adapted from89. 
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Figure 5.  
 
 
 
 
 
 
 
Figure 5. Glrx knockout increased Fasn, Scd1 and Hmgcr expression and Tnfα and 
IL-6 expression. Gene expression levels from RT-qPCR data (A) showing confirmation 
of Glrx KO in Glrx-/- mice (control for the experiment), and significantly increased Fasn 
and Scd1 expression in Glrx-/- livers compared to WT in both chow and HFHS diets 
(mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** p<0.001) (B) showing significantly 
decreased Glrx expression in Glrx-/- livers compared to WT, significantly increased Tnfα 
expression in Glrx-/- livers compared to WT on HFHS diet and significantly increased IL-
6 expression in Glrx-/- compared to WT on HFHS diet (mean±SEM, n=3-5, * p<0.05, ** 
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p<0.01, *** p<0.001). The nonparametric Mann–Whitney test was used to determine 
statistical significance. 
 
Glrx-/- mice fed chow and HFHS diet have increased antioxidant defense 
To first test if glutaredoxin deficient mice exhibited altered antioxidant defense, 
we analyzed Gsr and Gstp1 levels in both livers of WT and Glrx-/- mice fed chow diet and 
saw Gsr and Gstp1 mRNA levels were increased by Glrx deficiency (Fig. 6A.). These 
results suggest Glrx-/- mice that developed NAFLD have an elevated level of antioxidant 
defense shown by increased gene expression of Gsr and Gstp1. Secondly, to test the 
effect of lipogenic diet on antioxidant expression, we examined Gsr and Gspt1 levels in 
livers of WT and Glrx-/- mice fed HFHS and compared these results to levels seen in WT 
and Glrx-/- mice fed chow diet. Glrx-/- mice fed HFHS diet showed significant increase in 
Gsr and Gspt1 expression levels, while WT mice fed HFHS diet showed only a moderate 
yet still significant increase in Gsr and Gstp1 level compared to WT mice fed chow and 
HFHS diet (Fig. 6A). These results indicate that both Glrx deficiency and HFHS intake 
promotes expression of genes involved in antioxidant defense. In summary, these results 
suggest that impaired antioxidant defense caused by Glrx deficiency may be promoting 
the expression of antioxidant enzymes such as Gsr and Gstp1 by a compensatory 
mechanism.  
Next we looked at the effects of fasting on antioxidant levels and to see if Glrx 
deficiency would alter antioxidant expression levels during fasting, we looked at Gsr 
antioxidant expression levels in both WT and Glrx-/- mice fed chow diet (no fast) or 
	   55	  
fasted for 24 hr. The results of this experiment revealed no significant difference in Gsr 
expression levels in the non-fasted cohort in regards to genotypic difference between WT 
and Glrx-/- mice, but a significant difference in Gsr expression levels were seen in the 24 
hour fasted group, as Glrx-/- mice on 24 hour fast experienced a significant increase in 
Gsr expression levels compared to WT littermates on 24 hour fast (Fig. 6B.). We report 
that Glrx-/- mice on 24 hr fasting conditions had the most significantly increased Gsr 
levels by over five-fold compared to Gsr expression levels from Glrx-/- mice in the non-
fasting group. These results imply that period of acute fasting may have beneficial effects 
in raising the level of Gsr antioxidant expression as seen in livers of our Glrx-/- mice fed 
HFHS diet. Multiple studies have shown acute fasting or calorie restriction increase 
mRNA levels of antioxidant enzymes such as Glrx, Gsr, GCC and GSH synthase350. 
Other reports have shown one-three days fast in mice increased hepatic gene expression 
of Hmox1, SOD2, GSH-Prx, and Gsr, which are all key phase 2 detoxifying enzymes 
with the exception of Hmox1351. 	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Figure 6. 
 
 
  
 
 
 
 
Figure 6. Glrx-/- mice fed HFHS had increased Gsr and Gstp1 expression compared 
to WT mice but 24hr fasting also increased Gsr expression. Gene expression levels 
from RT-qPCR experiment (A) confirming Glrx KO in Glrx-/- mice and, significantly 
increased Gstp1 expression in Glrx-/- compared to WT on chow diet and significantly 
increased Gsr and Gstp1 expression in Glrx-/- compared to WT on both chow and HFHS 
diets (mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** p<0.001) (B) showing significantly 
increased Gsr mRNA expression in Glrx-/- compared to WT after 24hr fast, (mean±SEM, 
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n=3-5, * p<0.05, ** p<0.01, *** p<0.001). The nonparametric Mann–Whitney test was 
used to determine statistical significance. 	  
Glrx-/- mice fed HFHS showed increased Nrf2, Nqo1, Hmox1, G6pd, Sod1, Sod2, 
Me1, Tigar and Bbc3 
To test if Glrx deficiency alone could induce Nrf2 overexpression in livers with 
NAFLD phenotype, we measured and found no significant changes in Nrf2 expression 
between livers of WT and Glrx-/- mice fed chow diet but significantly increased Nrf2 
levels in livers of Glrx-/- mice fed HFHS diet compared to livers of WT mice fed HFHS 
(Fig. 7A.).  These results suggest that Nrf2 is expressed more in response to metabolic 
stress rather than in healthy mice fed normal diet. 
Next, downstream targets of the Nrf2/Keap1/ARE antioxidant signaling were 
investigated and all antioxidant protein expression were found to be elevated in livers of 
Glrx-/- mice fed HFHS compared to livers of WT mice fed HFHS (Fig. 7B.). With respect 
to gene expression levels, Nqo1 (1.73±1.0 fold), Hmox1 (1.45±0.34 fold), G6pd 
(4.13±2.3 fold), Sod1 (1.87±1.0 fold), Sod2 (1.38±0.3 fold), Me1 (1.84±0.31 fold), Tigar 
(1.49±0.4 fold), and Bbc3 (1.51±0.37 fold) were all increased in Glrx-/- mice compared to 
WT control.  These increases in gene expression of Nrf2 targets suggest activation of a 
wide array of metabolic pathways ranging from detoxification/antioxidant defense to 
lipogenic pathways in Glrx-/- mice fed HFHS diet. Noteworthy, the key enzyme of the 
PPP required for NADPH synthesis G6pd was also markedly upregulated (4.13±2.3 fold). 
NADPH feeds into anabolic processes and is required for glutathione, fatty acid and 
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cholesterol synthesis. This finding further supports our hypothesis that Glrx deficiency 
alters hepatic metabolism and promotes de novo lipo-biosynthesis. 	  
Figure 7. 
 
 
 
 
 
 
Figure 7. Glrx-/- mice fed HFHS showed increased Nrf2, Nqo1, Hmox1, G6pd, Sod1, 
Sod2, Me1, Tigar and Bbc3. (A) Representative bar graphs from RT-qPCR data 
showing significantly decreased Glrx mRNA levels in Glrx-/- compared to WT mice and 
significantly increased Nrf2 expression in Glrx-/- compared to WT mice fed HFHS diet 
(mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** p<0.001). (B) Representative bar graphs 
from RT-qPCR data showing significantly decreased Glrx mRNA expression and, 
significantly increased Nqo1, Hmox1, G6pd, Sod1, Sod2, Me1, Tigar and Bbc3 
expression in Glrx-/- compared to WT on chow diet (mean±SEM, n=3-5, * p<0.05, ** 
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p<0.01, *** p<0.001). The nonparametric Mann–Whitney test was used to determine 
statistical significance. 	  
HPHG and hydrogen peroxide treatment increased Nrf2 levels in HEK293A cells 
 To test whether lipogenic or oxidative stress increased the antioxidant response 
via Nrf2 activation, we measured protein levels of Nrf2 and Keap1 (endogenous Nrf2 
inhibitor) in HEK293A cells exposed to high palmitate high glucose (HPHG) and 
hydrogen peroxide (H2O2) respectively. On a side note, bovine serum albumin (BSA) was 
used to complex palmitate and avoid detergent like effects of FFA. Since palmitate is 
highly lipophilic, many researchers have been using BSA as a “carrier” to effectively 
shuttle palmitate through the plasma membrane352. Our results showed increased Nrf2 
(Fig. 8C.) and corresponding decreased Keap1 protein levels (Fig. 8D.) in HEK293A 
cells exposed to media containing either HPHG or H2O2. These results suggest Nrf2 is 
activated under lipogenic or oxidative stress conditions in HEK293A cells. 
To measure the effects of Glrx deficiency on Nrf2 levels under lipogenic and 
oxidative stress, we measured Nrf2 and Keap1 levels in HEK293A cells transfected with 
siGlrx in HEK293A cells and exposed to the same HPHG and H2O2 conditions. 
Knockdown of Glrx activity significantly increased Nrf2 and significantly decreased 
Keap1 in all conditions (Fig. 8F.-8G.). These results seem to suggest Glrx is directly 
associated with Nrf2 regulation and that Glrx might be functioning to repress Nrf2 
activity in HEK293A cells under homeostatic conditions. 
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Figure 8. 
 
 
  
 
 
 
 
 
 
 
Figure 8A. HPHG and hydrogen peroxide treatment increased Nrf2 levels in 
HEK293A cells. Representative WB bands showing increased Glrx and Nrf2 in HPHG 
and hydrogen peroxide treated cells (mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** 
p<0.001). 
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Figure 8B. - 8G. HPHG and hydrogen peroxide treatment to HEK293A cells 
increased Nrf2 levels. Representative WB bands showing (B) increased Glrx in HPHG 
and hydrogen peroxide treated cells (mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** 
p<0.001), (C) increased Nrf2 in HPHG and hydrogen peroxide treated cells (mean±SEM, 
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n=3-5, * p<0.05, ** p<0.01, *** p<0.001), (D) decreased Keap1 in in HPHG and 
hydrogen peroxide treated cells (mean±SEM, n=4, * p<0.05, ** p<0.01, *** p<0.001), 
(E) decreased Glrx in cells transfected with siGlrx in HPHG and hydrogen peroxide 
conditions (mean±SEM, n=3-5, * p<0.05, ** p<0.01, *** p<0.001), (F) increased Nrf2 in 
cells transfected with siGlrx with HPHG and hydrogen peroxide treatment (mean±SEM, 
n=3-5, * p<0.05, ** p<0.01, *** p<0.001) and (G) decreased Keap1 in cells transfected 
with siGlrx in HPHG and hydrogen peroxide conditions (mean±SEM, n=3-5, * p<0.05, 
** p<0.01, *** p<0.001). Statistical significance was determined by Mann–Whitney test. 
 
Glrx knockdown via siGlrx increased Nrf2 and Keap1 levels in HepG2 cells. 
Next we examined HepG2 cells, which were derived from a human hepatocellular 
carcinoma, to measure Nrf2 expression. To test whether knockdown of Glrx would affect 
Nrf2 levels in a highly lipogenic or oxidative environment HepG2 cells, we first 
measured Nrf2 levels in HepG2 cells transfected with siGlrx in both HPHG and H2O2 
treated conditions and found Nrf2 to be increased (Fig. 8C.) and Keap1 to be decreased 
(Fig. 8D.) in both conditions with siGlrx.	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Figure 9. 
 
        A. 
 
 
 
 
 
 
 
 
       B.                                         C.                                          D. 
  
Figure 9. Glrx knockdown via siRNA increased Nrf2 and Keap1 levels in HepG2 
cells. Representative WB bands showing A) decreased Glrx and increased Nrf2 and 
Keap1 in HepG2 cells transfected with siGlrx in HPHG and hydrogen peroxide 
conditions (mean±SEM, n=4, * p<0.05, ** p<0.01, *** p<0.001), (B) decreased Glrx 
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levels in siGlrx cells with HPHG treatment and siGlrx cells with hydrogen peroxide 
treatment (mean±SEM, n=4, * p<0.05, ** p<0.01, *** p<0.001), (C) increased Nrf2 
levels in siGlrx cells with HPHG and in siGlrx cells with hydrogen peroxide treatment 
(mean±SEM, n=4, * p<0.05, ** p<0.01, *** p<0.001) and (D) increased Keap1 in siGlrx 
cells with HPHG and in siGlrx cells with hydrogen peroxide treatment (mean±SEM, n=4, 
* p<0.05, ** p<0.01, *** p<0.001). The nonparametric Mann–Whitney test was used to 
determine statistical significance. 	  
Glrx knockdown via siRNA increased Nrf2 levels in HepG2 cells 
To test the extent to which lipogenic insult via HPHG treatment or oxidative 
stress via H2O2 treatment in HepG2 cells were responsible for inducing Nrf2 levels, we 
measured Nrf2 levels with Glrx knockdown via siGlrx without HPHG or H2O2 treatment. 
Our results showed increased Nrf2 and decreased Keap1 protein levels in HepG2 cells 
transfected with siGlrx compared to HepG2 cells treated with BSA (Fig. 10B.-10C.). 
These results indicate that Glrx regulates Nrf2. 
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Figure 10. Glrx knockdown via siRNA increased Nrf2 levels in HepG2 cells. 
Representative WB bands showing (A) decreased Glrx and increased Nrf2 in HepG2 
cells transfected with siGlrx (mean±SEM, n=4, * p<0.05, ** p<0.01, *** p<0.001) (B) 
decreased Glrx levels in siGlrx cells (mean±SEM, n=4, * p<0.05, ** p<0.01, *** 
p<0.001) and (C) increased Nrf2 levels in siGlrx cells (mean±SEM, n=4, * p<0.05, ** 
p<0.01, *** p<0.001). The nonparametric Mann–Whitney test was used to determine 
statistical significance. 
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DISCUSSION 
 
The exact role of Glrx in oxidative stress is still under investigation and there 
exist contradictory reports on the regulatory role of Glrx in redox homeostasis. Under 
oxidative stress, increased ROS production has been shown to drive glutathionylation of 
free thiols (-SH) of cysteine residues of proteins to form PSSG353. In normal livers of 
healthy individuals, PSSG levels have been shown to constitute 1% of total cellular GSH 
levels354 but under oxidative stress PSSG has been shown to be increased to reach as high 
as 20-50% of total cellular GSH levels355. Studies conducted on retinoblastoma cells and 
eye lenses showed that Glrx decreased oxidative stress and attenuated oxidative 
damage356–358. Reports from hepatoblastoma cells similarly demonstrated that decreased 
antioxidant defense by Glrx gene silencing resulted in increased oxidative stress359. In 
astrocytoma cells, inhibition of Glrx by methylmercury was shown to lead to an increase 
in GSSG levels, and hydrogen peroxide production as well as inhibition of GSH 
synthesis. These results demonstrate altered Glrx deficiency can effect GSH homeostasis, 
lead to increased S-glutathionylation of proteins (PSSG) and oxidative stress360. Glrx has 
also been shown to be implicated in protection against copper induced oxidative damage 
in neuroblastoma cells358. Despite these correlations in research linking Glrx’s protective 
role to reduced oxidative damage, there exists conflicting results regarding Glrx’s impact 
on oxidative stress. 
Previous studies from our group showed that livers of Glrx-/- mice that developed 
NAFLD but did not develop significant oxidative stress89. Earlier studies from our group, 
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looking at protective effects of Glrx on cardiac hypertrophy, showed that angiotensin II 
infused Glrx-/- mice also did not exhibit oxidative stress361. Additional studies performed 
on Glrx-/- mice subject to ischemia/reperfusion or hypoxia showed no indication of 
oxidative damage362. One study using endothelial cells isolated from T2DM patients and 
on Glrx TG ApoE-/- fed Western diet, reported an increased level of metabolic stress-
mediated protein S-glutathionylation (GSH adducts) but did not show significant changes 
in GSSG/GSH levels, which is definitive of oxidative stress262. Also, Glrx KO mice 
subject to hind limb ischemia showed increased protein S-glutathionylation (GSH 
adducts) as well as increased angiogenesis and vascularization but showed no indication 
of oxidative damage363,364. Overall, these results seem to suggest that Glrx overexpression 
decrease S-glutathionylation (GSH adducts) to promote anti-angiogenic properties365–367, 
while Glrx-deficiency increases S-glutathionylation (GSH adducts) to stimulate 
angiogenic processes368. However, the fact that our Glrx-/- mice do not exhibit significant 
changes in GSSG levels that is indicative of oxidative stress despite increased S-
glutathionylation of protein (PSSG) suggested an alternative regulator may be mediating 
antioxidant defense in these animals. We hypothesized that Nrf2 was acting downstream 
of Glrx antioxidant system to induce expression of GSH synthase to catalyze the 
production of GSH. 
It was recently published that our Glrx-/- mice on NJ background (normal-J; 
without NNT deletion) fed normal diet (ND) and high fat diet (HFD) rich in cholesterol 
developed obesity, hyperlipidemia and NAFLD phenotype independent of oxidative 
stress and IR by eight months of age89. These Glrx-/- mice on NJ background were also 
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shown to exhibit an increased low-density lipoprotein (LDL) to very low-density 
lipoprotein (VLDL) ratio, without changes in overall high-density lipoprotein (HDL) 
concentrations, suggesting an altered cholesterol metabolism89. Consistent with findings 
from Shao et al., the livers of Glrx-/- mice on J background were significantly enlarged at 
ten months of age as compared to WT littermates. Multiple histological methods 
including Oil Red O and H&E staining confirmed hepatic steatosis in livers of Glrx-/- 
mice on both J and NJ backgrounds (Fig. 3. and Fig. 4.).  
Prior experiments by Shao et al. also reported increased plasma ALT and AST 
levels but no changes in overall AST/ALT ratios in Glrx-/- mice compared to WT mice 
with NJ background. These results combined with results taken from liver enzyme 
assessment, Shao et al. showed an absence of hepatic inflammation or oxidative injury in 
livers of Glrx-/- mice fed chow diet. Also reported was an increase in protein glutathione 
adducts (PSSG) in Glrx-/- livers via detection with a GSH specific antibody. Even though 
the results showed that the livers of Glrx-/- mice had higher levels of PSSG, comparable 
levels of oxidized glutathione disulfide adducts (GSSG) were seen in both livers of Glrx-/- 
mice and WT littermates, which serves as a negative indicator of oxidative stress. This is 
likely due to impaired GSH homeostasis brought upon by Glrx deficiency and increased 
NADPH levels as increased Gsr activity was reported in Glrx-/- mice fed HFHS diet (Fig. 
6A.). These results ultimately implied there might be an increased level of reversible 
oxidative modifications that occur in Glrx-/- livers in absence of oxidative stress and Glrx 
KO in liver could be promoting hepatic DNL independent of oxidative stress that is 
contributing to the underlying pathogenesis of NAFLD89. Furthermore, glutathione 
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constitutes the cells redox buffer and increasing intracellular GSH levels will render the 
cytoplasm more reducing. This effect could be counter regulatory to limit GSH adducts 
and promote their reduction. 
In contrast to Shao et al. findings, we showed an increase in mRNA expression of 
inflammatory cytokines Tnfα and IL-6 in livers of our Glrx-/- mice fed both chow and 
HFHS diet (Fig. 5B.), which could be a result of NNT deletion in our mice. Its important 
to mention that results from Shao et al. used Glrx-/- mice with NJ background (strain 
without NNT deletion) fed a cholesterol rich diet while results from this experiment were 
taken from Glrx-/- mice with J background (strain with NNT deletion) fed high fat high 
sucrose (HFHS) diet.  With acknowledgment to differences in mouse strain and diet 
between the two studies, it became apparent that Glrx-/- mice with NJ background 
developed hepatic inflammation only in response to a second hit, which was high 
cholesterol consumption. As NNT mutation leads to altered dysfunction in mitochondrial 
respiration, increased production of hydrogen peroxide, and impaired redox status of 
GSH369, it was not surprising to find that these Glrx-/- NNT-/- mice were more susceptible 
to hepatic inflammation as seen by increased expression of Tnfα and IL-6 on chow diet 
(Fig. 5B.). Various reports support this finding and have demonstrate that J mice are 
more susceptible to metabolic disorders370. 
To show Glrx-/- livers developed obesity fed chow diet for ten months, mRNA 
expression levels of Fasn, Scd1 and Hmgcr, which are all regulators of DNL biosynthesis 
in liver, were increased in Glrx-/- livers compared to WT livers (Fig. 5A). Overall, our 
results supported Shao et al. findings and confirmed Glrx KO in liver promoted hepatic 
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fatty acid deposition and inflammation that led to NAFLD development. The effects were 
exacerbated when Glrx-/- mice were fed HFHS diet, as one can see by significantly 
increased expression of Tnfα and IL-6 in Glrx-/- mice fed HFHS compared to chow diet 
(Fig. 5B.). All experiments were performed according to the instructions of Shao et al. 
and our findings supported the development of obesity and NAFLD in our Glrx-/- mice on 
NJ background independent of oxidative stress or IR. 
Glrx plays a critical role in redox homeostasis by increasing GSH levels via 
reversal of de-glutathionylation on proteins371. In our study we reported that Glrx-/- mice 
fed chow and HFHS diet had increased Gsr and Gstp1 levels indicative of heightened 
antioxidant defense (Fig. 6A). Studies have confirmed that Glrx-/- mice have increased 
antioxidant defense due to lack of Glrx, which has proven to be a crucial player in 
antioxidant defense by acting as a thiol repair enzyme that catalyzes the reduction of 
PSSG to produce GSH372.  On another note, the fact that Glrx is abundant in liver and 
more importantly, contains two reactive cysteines372, would explain why our Glrx-/- mice 
displayed no indication of oxidative damage in liver.  
GSH synthesis is tightly regulated by Gsr, which regenerates GSH from GSSG 
using NADPH as a cofactor. In our study we reported that Glrx-/- fed chow diet had 
increased Gsr expression levels following a 24hr fasting period (Fig. 6B). Prior studies 
have shown that pre-operative fasting of 1-3 days induced protection on mouse livers by 
activating gene expression of key antioxidants such as Hmox1, Sod2, Gpx, and Gsr351. 
Additional studies have also reported the beneficial cytoprotective effects of fasting. In 
one study, 1-2 days of fasting were shown to induce Nrf2 mediated antioxidant gene 
	   71	  
expression of Hmox1 and Gstp1373. In a study looking at the impact of reduced GSH on 
expression of antioxidant genes in response to oxidative stress, it was reported that a 
decrease in GSH increased Nrf2 and decreased Glrx levels374. Studies have confirmed 
reduced GSH levels due to oxidative stress lead to over-activation of c-Jun N-terminal 
kinase (JNK)/c-Jun signaling that induces hepatic steatosis and inflammation261. 
Additional studies in retinal pigment epithelial (RPE) cells found that Nrf2 induced 
increased gene expression of antioxidants including antioxidant regulating enzyme 
Glrx374. We hypothesized that our Glrx-/- mice fed HFHS diet would have increased Nrf2 
expression compared to WT mice fed HFHS diet and our gene and protein studies 
supported our hypothesis showing increased Nrf2 mRNA expression and protein levels in 
Glrx-/- mice compared to WT littermates fed HFHS (Fig. 7A). 
Aforementioned, all down-stream signaling targets of Nrf2 were upregulated. In 
our experiments, G6pd was increased by at least four-fold in Glrx KO compared to WT. 
As discussed G6pd is the key antioxidant enzyme in PPP that plays an essential role in 
defense against oxidative stress by producing NADPH, which is the main intracellular 
reductant by various NADPH dependent enzymes such as Trx, and Gsr, which rely upon 
NADPH as a reducing equivalent for redox reactions. G6pd by being the main enzyme in 
generating NADPH has shown to maintain low GSSG/GSH levels (prevent oxidative 
stress by keeping GSH in reduced state)358.  In APO-/- mice (with G6pd deficiency) fed 
HFD, studies have shown there is lower oxidative stress but no changes in 
antioxidants375. Rats fed high sucrose diet induced NAFLD, reported to have increased 
G6pd antioxidant activity and reduced GSH that was associated with worsened NAFLD 
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severity375. These results suggest other enzymes may be regulating levels of NADPH 
levels, which is required for antioxidant activity as well as fatty acid and cholesterol 
synthesis which may be contributing to NAFLD pathogenesis. Our results are consistent 
with increased G6pd in response to high sucrose diet but aside from earlier findings we 
found no indication of decreased oxidative stress in Glrx-/- mice89.  As shown in the 
results section, the levels of antioxidants were greatly increased in our Glrx-/- mice, G6pd 
was increased by at least four fold and Me1 was increased by approximately 2 fold in 
Glrx-/- compared to WT mice (Fig. 7B.). Also shown in our results was a significant 
increase in Gsr in Glrx-/- compared to WT mice. The significant increase in antioxidant 
gene expression (NADPH producing enzymes G6pd, Me1 and Gsr) would lead to an 
increase in NADPH species, which could explain the increase in anabolic process that 
ultimately results in hepatic steatosis in our mice. Thus, future work requires measuring 
PSSG (GSH adducts), GSSG, GSH, or NADPH/NADP+ levels, to better understand the 
effects of Glrx-deficiency on the antioxidant system. 
Prior studies have already demonstrated the presence of oxidative stress in 
patients with NAFLD376,377. To confirm whether oxidative stress occurred in our Glrx-/- 
mice, we examined gene expression of Nrf2 and downstream targets of Nrf2. We saw 
increased gene expression of Nrf2 and targets of Nrf2 in livers of Glrx-/- mice fed HFHS 
diet compared to livers of WT mice fed HFHS (Fig. 7B). Increased Nrf2 activation and 
increased expression of Nrf2 targets has already been shown in livers of Keap1 KO mice 
predisposed to NAFLD phenotype298. Studies have also supported that lipogenic diet 
serves a causative role in the development of obesity and its associative metabolic 
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complications including NAFLD300. Now new research also supports induction of Nrf2 
and its down signaling targets with HFD induces NAFLD300,374. One study, which looked 
at Nrf2’s role in lipid metabolism, reported higher levels of gene expression of Nrf2 and 
Nrf2 target genes in WT mice fed a cholesterol rich diet compared to Nrf2-null mice fed 
the same diet288. Our results also supported these claims by showing that HPHG and 
H2O2 treatment to HEK293A cells increased Nrf2 protein levels (Fig. 8C.) but Glrx 
knockdown (KD) using siGlrx in HEK293A cells for each of these treatment conditions 
was shown to increase Nrf2 protein levels (Fig. 8F.). Nrf2 protein levels were also shown 
to be increased in HepG2 cells transfected with siGlrx treated with HPHG and H2O2 (Fig. 
9C.) but an more significant increases in Nrf2 protein levels were shown in HepG2 cells 
with Glrx KD alone (Fig. 10C.). All these results seem to suggest that Nrf2 may play a 
direct role in antioxidant defense in Glrx-deficiency upon lipogenic or oxidative insult. 
In summary, Nrf2 has been described as an oxidative stress mediated transcription 
factor and its role in detoxification and cytoprotection has been studied extensively over 
the past decade. Recently, Nrf2 has been regarded as a new therapeutic target in the 
treatment of fatty liver disease like NAFLD and NASH due to its wide-ranging effects on 
antioxidant defense and lipid metabolism. Reports have confirmed depletion of GSH lead 
to oxidative stress and mitochondrial dysfunction induced cell death and 
inflammation378,379. In human studies, NAFLD has been proposed to be the manifestation 
of decreased GSH synthesis from altered GSH metabolism380. In mouse model, it has also 
been shown that increased GSH and NADP+ production from disturbed redox 
homeostasis is associated with increased expression of lipogenic genes and increased 
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severity of hepatic steatosis381,382. Our results showed increased Nrf2 expression in livers 
of Glrx-/- mice fed HFHS diet compared to WT mice fed the same diet. The results from 
this study provide strong evidence that Glrx-deficiency likely exacerbates obesity/diet 
induced dysfunction in lipid metabolism and lead to the induction of Nrf2.
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